biotechnology basque country

138
Portfolio of Biotechnology Opportunities in the Basque Country BioChemTech Sector Group

Upload: spri

Post on 13-May-2015

1.736 views

Category:

Business


0 download

DESCRIPTION

Portfolio of biotechnology Opportunities in the Basque Country. Biochemtech Sector Group. Digital edition also in ebook formats. www.spri.es/doc/biotechnology-portfolio

TRANSCRIPT

Page 1: Biotechnology Basque Country

Portfolio of Biotechnology Opportunities in the Basque Country

BioChemTech Sector Group

Page 2: Biotechnology Basque Country

2

Page 3: Biotechnology Basque Country

Portfolio ofBiotechnology Opportunities

in the Basque CountryBioChemTech Sector Group

3

Page 4: Biotechnology Basque Country

INDEX

Index................................................ 4

Introduction .................................... 6

Technology Offers:HEALTH .............8

AJL OPHTHALMIC SA (AJL) ...................................................... 10Design, development and manufacture of intraocular lenses and other medical devices

BIAL .................................................................................... 12Recombinant Allergens

BIOBIDE S.L, ........................................................................ 14Toxicity and efficacy assays of compounds through zebrafish animal model

BIOFISICA FRET .................................................................... 18FRET Amplified Signal Technology for Biomarker And System Evaluation- (FASTBASE)

BIOFISICA OIT ...................................................................... 22Biofisika Open Innovation Platform (Biofisika-OIP)

BIOFTALMIK ......................................................................... 26Tear based diagnostic test for ocular diseases

BRAINCO BIOPHARMA S.L ...................................................... 30An innovative target for the detection and treatment of Depression

BRAINCO BIOPHARMA S.L ...................................................... 32Small molecules for the treatment of Schizophrenia

CEIT .................................................................................... 34Pyrogenic agents (endotoxins) detection both in fluids (biological reagents, pharmaceutical products) and in medical devices

CEIT .................................................................................... 38Software and Hardware for biomedical applications

CEIT .................................................................................... 40Systems Biology

FuNDACIóN CIDETEC-IK4 ...................................................... 42Biomaterials Synthesis and Electrochemistry

DYNAKIN, S.L. ...................................................................... 46Dynakin, strategic decision assistance for drug development via regulatory, Modeling & Simulation, Clinical Trial design and execution and GLP Biolab departments in four central European countries

GAIKER-IK4 .......................................................................... 50In Vitro Diagnostic tests

GAIKER-IK4 .......................................................................... 52Preclinical in vitro services

GAIKER-IK4 .......................................................................... 56Industrial biotechnology

4

Page 5: Biotechnology Basque Country

HISTOCELL ........................................................................... 60GMP production of different cell therapy products

HISTOCELL ........................................................................... 62Novel cell and tissue storage and shipping technology

IKERLAT Polymers, S.L. ......................................................... 66Organic and inorganic dispersions for diagnostic reagents and biological/biotechnological fields

INBIOMED ............................................................................ 68Derivation of human induced Pluripotent Stem Cells (iPSC-s)

INBIOMED ............................................................................ 70GMP standards in viral vector production and flow cytometry

IK4-TEKNIKER ....................................................................... 72Biosensors and micro/nanostructuring technologies

INNOPROT ............................................................................ 74Cell-based Assay Development

INNOPROT ............................................................................ 76Recombinant stable cell line for secretase activity assessment of potential drugs for Alzheimer’s disease

INNOPROT ............................................................................ 78NomadTM Technology: The New Generation of Biosensors for HCS

LABORATORIuM SANITATIS, S.L. TECNALIA ............................. 80Pharmaceutical development, scale-up and manufacturing of medicinal products and investigational medicinal products for clinical trials

LABORATORIuM SANITATIS, S.L. TECNALIA ............................. 84Development and manufacturing of lipid nanoparticles as drug delivery systems

METAL ESTALKI, S.L. .............................................................. 86PVD ceramic coating for biotechnology and medical applications

ONDAX SCIENTIFIC S.L. ......................................................... 88Clinical Trials in Animal Health

OWL GENOMICS .................................................................... 90Metabolomics and Lipidomics products an services provider

PRAXIS BIOPHARMA RESEARCH INSTITuTE .............................. 94Pharmaceutical products development and production

PRAXIS PHARMACEuTICAL ...................................................... 96Pharmaceutical products production and distribution

PROGENIKA BIOPHARMA S.A. ................................................. 98Functional genomics services

PROTEOMIKA .......................................................................100Monitoring of biological therapies

uPV ....................................................................................104Preparation of magnetic biocatalysts and its uses in industry and biomedicine

VACuNEK, S.L. .....................................................................106Developing novel vaccines for animal mycobacteriosis and nucleic acid

amplification tests (NAATs) for animal diseases

VICOMTECH .........................................................................108Computer Graphics, Visual Computing and IT Solutions for the Processing, Analysis and Visualization of Biomedical Data and Knowledge

Technology Offers: AGRI-FOOD .... 112BIOFuNGITEK ......................................................................114

Fungicide and biostimulant products for control of main agricultural fungal disease

CIC NANOGuNE ...................................................................116Spun food

BIOLAN MICROBIOSENSORES S.L ...........................................118Biosensors for the agro-food industry

Technology Requests: HEALTH ... 120GENETADI BIOTECH ..............................................................122

Biosensor Instruments for In-Vitro Diagnostic Testing

GENETADI BIOTECH ..............................................................123Development of new “in-vitro” and “in-vivo” methods to identify and isolate specific human DNA-regions previous to high-throughput DNA sequencing

HISTOCELL ..........................................................................124New biomaterials for tissue engineering and cell therapy products

INBIOMED ...........................................................................125Bioreactors and large viral purification systems

INBIOMED ...........................................................................126Superesolution techniques/modules and long-term incubation modules for in vivo assays in confocal microscopy

INNOPROT ...........................................................................127Genetically-Encoded Fluorescent Biosensors

PROTEOMIKA .......................................................................128Technological partners to develop new ELISA products for monitoring biologic therapies

LABORATORIuM SANITATIS, S.L. TECNALIA .............................130Pharmaceutical Products and Services

Services ........................................132ELuR ..................................................................................134

Your Partner for Biotechnology facilities and Pharmaceutical Industry

NESPLORA ...........................................................................136Research and Development of Technology solutions for the Neuroscience: Diagnostic, Treatment, Basic Research and Prevention

5

Page 6: Biotechnology Basque Country

Introduction

6

Page 7: Biotechnology Basque Country

Basque Bioregion: BioBasque and the Basque BioCluster

Strategic public-private collaborative frame-work for the development of life Science in the baSque country

Over the last two decades, the Basque Government has undertaken scientific and technological policies which support the existing industrial fabric, but also prepare the Basque Country for future challenges by means of diversification into knowledge intensive sectors. The commitment to life sciences has been developed as a specific results-driven policy known as BioBasque Strategy. Strong government support with a pro-business orientation has helped the development of a thriving biosciences community, promoting the collaboration between the academic world, the health system and industry. Proven experience in clustering has also worked to create a nourishing environment that acts as a magnet for talent. Within this favourable framework, an attentive to technological revolutions private sector and an entrepreneurial spirit become assets for consolidating the Basque Biocluster. The role of the BioBasque Agency, hosted by the Basque regional development agency SPRI, during the last 10 years of implementation of BioBasque strategy has been to facilitate the emergence of the Basque bioregion, being its mission to align all horizontal public instruments for business promotion (R&D programmes, entrepreneurial support, venture capital, talent attraction programmes…) towards the specific aim of the creation of the Basque Biocluster.

Since the creation of the Basque Biocluster in 2010, the close relationship between the two entities have paved the way for the consolidation of the small but vibrant Basque Bioregion with two main streams of activities: consolidation of the already existing biocompanies and promote the growth of the biocluster. Concrete ongoing examples are the development of a joint international commercialization platform for the biocompanies and the deployment of a sophisticated portfolio of services for bioincubation. The experience gained in the implementation of BioBasque strategy serves now as a basis for the design of the Basque Smart Specialisation Strategy.

To find out more information, please visit:

http://www.biobasque.orghttp://basquebiocluster.com

Enterprise Europe Network

buSineSS Support on your doorStep

The Enterprise Europe Network is a unique network made up of some 600 business support organisations in more than 50 countries throughout the European union (Eu) and beyond. It is dedicated to helping SMEs to make the most of the business opportunities in the EU.

Launched in 2008 by the European Commission, the Enterprise Europe Network is the largest network in Europe providing expertise and services for businesses. The new Programme for the Competitiveness of Enterprises and Small and Medium-sized Enterprises (COSME), which will run from 2014 to 2020 and aims to encourage the growth and competitiveness of European firms, will ensure the continuity of the Enterprise Europe Network, building on previous results and lessons learnt.

The mission of the BioChemtech Sector Group is to provide a niche service to one of Europe’s most important sectors: Biotechnology and Chemistry. This includes a comprehensive and high quality European knowledge transfer, information and business support service for organisations, particularly SMEs, with a view to increasing their competitiveness and promoting their overall economic growth.

Basque Enterprise Europe Network consists of SPRI, Innobasque, Alava Chamber of Commerce, Bilbao Chamber of Commerce, Guipuzcoa Chamber of Commerce and BEAZ.

To find out more information, please visit:

http://een.ec.europa.euhttp://www.eenbasque.net/

7

Page 8: Biotechnology Basque Country

8

Page 9: Biotechnology Basque Country

Technology Offers

Health

9

Page 10: Biotechnology Basque Country

abStract of technology to exploit

AJL OPHTHALMIC is the unique Spanish company dedicated to the design and manufacture of intraocular lenses and other ophthalmologic implants. Its premises are provided with all the required machinery and technology to produce and package ophthalmologic implants and other products involved in eye surgery. Moreover, AJL is part of many innovative projects with the aim of improving its technology and offering last generation products and services.

deScription

AJL OPHTHALMIC, S.A. is a young and dynamic company which began its activity in the design, manufacture and distribution of medical devices within the field of ophthalmology in April 1998 and still continues working on the development of new intraocular lenses and other products of application in intraocular surgery. Our offer includes:

• Design of new ophthalmological implants, manufacture, sterilization and commercialization of intraocular lenses and other medical devices as well as a wide variety of products and instruments used in surgery.

• Availability of clean rooms ISO5 / ISO6 / ISO7 for product assembling and packing for third parties.

• Possibility of sterilization in clean room and packaging in rigid blister.

• Laser marking of surgical instruments or others for product customization.

• Availability of classrooms for surgical training courses and Wet Labs for the diffusion of the last clinical procedures and researches in ophthalmology.

innovative aSpectS

We are involved in many innovative projects in order to achieve the latest available technology and thus, offer a high-tech production process and products. Our projects are directed to the following fields:

promoter organization identification

organization name AJL OPHTHALMIC SA (AJL)

contact Eva Larra

email [email protected]

phone +34/945298256-289

fax +34/945298209

description of the organization

Private Company

activity Manufacture and distribution of intraocular lenses and medical devices for ophthalmologic surgery

markets tackled Optical and health sectors

Size SME

Design, development and manufacture of intraocular lenses and other medical devices

10 Technology Offers · HealTH

Page 11: Biotechnology Basque Country

• Microprocessing of optical quality surfaces. We have available optical inspection equipment.

• New generation of materials and 3D Printing for advanced manufacturing.

• Design of Biocompatible and Customized interfaces, surface and coatings for Intra Ocular Lens

• Developments in tissue regeneration combining growth factors and mesenchymal cells.

• New maxillofacial implant designs.

main advantageS

The technology and products used in AJL OPHTHALMIC are directed to human health, being specialized in the ophthalmology field, therefore all the materials and processes we use are biocompatible with human tissues, and we also have the machinery to manufacture our implants and provide them sterility. In addition, we collaborate in many projects and work hard in new designs to keep growing as a company in order to cover the needs of the patients.

Furthermore, our facilities are open to interaction with ophthalmologists or other medicine specialists, offering training courses or displays of new surgical procedures and serving at the same time as a meeting point to understand better the arising demands.

applicability of the technology

Our product offer includes:

• Manufacture of ophthalmologic devices:

· Intraocular Lenses (IOLs): PMMA, HEMA, foldable, injectable.

· Other implants: Intracorneal rings and segments, orbital implants (Oculfit) or for retinal detachment treatment (Macular Buckling), among others.

· Injectable solutions and stains: Viscoelastic, Silicon Oil or Typan Blue.

· Glaucoma treatment: Esnoper, a non-reabsorbible scleral implant, designed to improve the drainage of aqueous hu-mour after undergoing Non-Penetrating Deep Sclerectomy.

• Laser marking, packaging and sterilization of other surgical products and instruments.

current Stage of development

Currently we have many commercialised implants and other devices that are manufactured with validated equipment and processes. For further information you can visit on our website all the available products (www.ajlsa.com).

exploitation of rtd reSultS

The products and technologies developed by AJL OPHTHALMIC SA are mostly the result of own funds, and have been also helped by projects supported by public entities.

intellectual property rightS

AJL holds two key patents on implants design:

• Multifocal Ophthalmic Lens and its obtention process, Reference number 201031316.

• Scleral Epimacular Implant, Reference number 12382348.

All the products made in AJL have obtained the EC certificate, which assures the fulfilment of all the essential requirements established in the Directive 93/42/CEE on medical devices.

Quality management system according to standards ISO 13485 and ISO 9001:2000.

collaboration type

Open to all type of collaboration with industry, research centres or universities.

Technology Offers · HealTH 11

Page 12: Biotechnology Basque Country

abStract of technology to exploit

We offer recombinant allergens for diagnosis and treatment of allergic diseases.

deScription

Recombinant allergen allows a component resolved diagnosis of the allergic pathologies. Thus, patients who are allergic for instance to grass pollen, could know in detail –by cutaneous or in vitro tests– which is the responsible protein of their pathologies. Recombinant allergens can be easily coupled to membrane or plastic supports to allow quick individualized diagnosis. They can also adapt to microarrayed diagnostics devices.

innovative aSpectS

Most of commercial allergens used for diagnosis and all the ones used for allergic treatment (vaccines) consist of natural multiproteinic extracts. Recombinant allergens constitute an innovation, since the use of more defined, pure and reproducible substances can dramatically improve the clinical efficacy of the variability affected natural products.

main advantageS

Recombinant allergens (RA) are much more reproducible than the natural extracts used so far for diagnosis and treatment (vaccines) of allergic diseases.

RA are not affected by the variability of natural extracts from biological origin. Products for diagnosis and treatment based on RA can be prepared without the need of collecting the natural raw materials.

RA can be more specific for diagnosis of allergy, since it can provide information of the precise protein molecules which elicit

promoter organization identification

organization name BIAL INDuSTRIAL FARMACÉuTICA S.A. (Bial-Arístegui)

contact Alberto Martínez Gárate

email [email protected]

phone +34 944 438000

fax +34 944 438016

description of the organization

Bial is a private pharmaceutical company which produces human medicines (allergenic vaccines and PMPs)

activity Manufacturing, commercialization and research of human medicines

markets tackled Pharmaceutical market

Size Large industry

Recombinant Allergens

12 Technology Offers · HealTH

Page 13: Biotechnology Basque Country

the allergic reaction in every patient.

RA can be more efficacious for the treatment of the allergic patients.

applicability of the technology

More than a technology, what we are interested in offering is a product (RA) which can be used for manufacturers of diagnostics or vaccines in the field of allergic diseases.

current Stage of development

Currently we have many commercialised implants and other devices that are manufactured with validated equipment and processes. For further information you can visit on our website all the available products (www.ajlsa.com).

exploitation of rtd reSultS

The products developed so far are a result of our own research, mainly with our own funs and partial supports from Basque and Spanish Government.

intellectual property rightS

Most of the RA developed have been patented by us, at national (more frequently) or international level. Some others have been left open to public domain.

collaboration type

Any kind of collaboration could be explored, from a simple sale to license sharing or co-development.

Technology Offers · HealTH 13

Page 14: Biotechnology Basque Country

abStract of technology to exploit

BBD BioPhenix has developed several toxicity and efficacy assays through the in vivo vertebrate zebrafish animal model. These assays analyze the toxicity and efficacy of compounds increasing the number of compounds tested faster and in a more cost-effective way.

Toxicity assays already developed are acute toxicity, cardiotoxicity, teratogenicity, hepatotoxicity, neurotoxicity and otic toxicity. Efficacy assays are developed in oncology, neurodegenerative diseases and metabolism and inflammation areas mainly. These assays are carried out in early stages of the Drug Discovery process, prior to preclinical test in mammals, making a better selection of the best candidates. In addition, some of the assay has been automated through our High Content Screening (HCS) platform allowing a higher repeatability.

Finally, Tailor-made solutions depending on specific requirements are developed having into account clients´ specific need.

deScription

BBD BioPhenix is a Contract research Organization (CRO) that aims to help our customers worldwide developing tailor-made solutions to maximize their R+D productivity and minimize risks in the this process, integrating zebrafish animal model with innovative tools such as image analysis and automation.

The company is located in GuipuzkoaTechnological Park, in San Sebastian, Spain, where among its modern installations has a zebrafish facility for housing up to 50,000 adult zebrafish, from different transgenic and/or mutant lines to allow several specific toxicity and efficacy assays.

target validation: though Morpholinos

disease models generations: in different therapeutic areas

Toxicity and efficacy assays of compounds through zebrafish animal model

promoter organization identification

organization name BBD BioPhenix S.L.-Biobide

contact Arantza Muriana

email [email protected]

phone 0034-93 309360

fax 0034-93 309370

description of the organization

CRO (Contract Research Organization)

activity Biotechnology Company offering preclinical services using zebrafish animal model for pharmaceutical, biotechnology, chemical, veterinary, cosmetic and natraceutical industries. This alternative model combines the advantages of in vitro and in vivo models, in the area of toxicity, safety and efficacy of drugs or agrochemicals, petrochemicals, functional foods or cosmetics.

markets tackled Pharmaceutical, Biotech, Agrochemical, Petrochemical, Functional Food and Cosmetic industries.

Size 7 employees

14 Technology Offers · HealTH

Page 15: Biotechnology Basque Country

by transgenesis (through TALENS technology) or mutagenesis.

toxicity assays:

• acute toxicity assay. This assay based on a draft of an OECD guideline evaluates the presence of 3 different endpoints.

• cardiotoxicity assay: This fully automated assay through our HTS platform evaluates QT prolongation, presence of arrhythmia, bradycardia as well as cardiac arrest.

• teratogenicity/developmental toxicity assay: In a week period 40 different endpoints are identified and measured.

• hepatotoxicity assays: Different assays have been developed in this area as it constitutes the second cause of drug withdrawal.

• neurotoxicity assays: Behavior alteration tracking in zebrafish by the Noldus automated system.

• otic toxicity assay: Otic toxicity can be analyzed by counting the number of neuromasts (mechanosensory organs in zebrafish).

• tailor-made solutions: Different toxicity assays can be adapt or developed depending on customer requirements.

Efficacy assays:

• Oncology:

· Angiogenesis Inhibition Assay.

· Screening in tumoral models: melanoma, hepatocarcinoma,…

• cnS:

· Antiepileptogenic Assay.

· Screening on neurodegenerative disease models: Parkinson´s Disease (PTZ…), Alzheimer´s diseases …

• Metabolism:

· Lipids metabolism, obesity, diabetes….

innovative aSpectS

BBD BioPhenix is structured around the zebrafish vertebrate animal model that allows combining in vitro and in vivo advantages to work under the 3 R´s, decreasing number of animals used.

Its aim is to reduce the time and the cost required for the Drug development process, increasing the compound success rate and decreasing the failures ratio due to adverse side effects, throughout the drug research and development process. The objective is to detect the compounds that due to their toxicity would be discarded at the end of the Drug Discovery process, but in very early stages of it.

Zebrafish embryos are ideal to integrate toxicity and efficacy assays, ensuring a high number of compounds tested in a short period of time, and with a lower cost. In the other hand, automation increases repeatability.

main advantageS

BBD BioPhenix will allow companies to focus their R&D efforts and

Technology Offers · HealTH 15

Page 16: Biotechnology Basque Country

investments in their new compounds with the highest success rates among the Drug Discovery process, due to their proven efficacy, for a better selection of successful candidates.

applicability of the technology

For Pharmaceutical and Biotechnology Companies, Chemical Companies (Petrochemical or Agrochemical), Functional Food Companies, Cosmetic in early stages of Drug Discovery process, prior to preclinical test on mammals, for mass screening of potential drugs or lead optimization, or even re-profiling of compounds.

Applicability: toxicity assays for potential new drugs, petrochemical compounds, pesticides and fungicides, natraceuticals and cosmetics; as well as efficacy assays for potential new drugs.

current Stage of development

Those assays are validated manually and / or automated for reference products, and are developed under GLP standards and using the most innovative technologies.

exploitation of rtd reSultS

All the different assays are product of our own know-how and development.

collaboration type

• Outsourcing of already developed assays

• Tailor made solutions

· Customization of established assays

· Further development of ongoing projects

· Development of new applications

16 Technology Offers · HealTH

Page 17: Biotechnology Basque Country

Technology Offers · HealTH 17

Page 18: Biotechnology Basque Country

abStract of technology to exploit

FASTBASE offers an advanced diagnostic technology in the field of oncology both for pharmaceutical and academic purposes. This technology permits to quantify, protein activation states and protein-protein interactions. The technology has already been tested and validated in human tumour biopsies to detect biomarkers with the aim to help diagnosis and treatment prescription of patients, but can be also applied to many other diseases, as cardio-vascular and neurodegenerative diseases.

The technology is based on a novel methodology, known as amplified-time resolved-Förster Resonance Energy Transfer (FRET), utilised for assessing oncoprotein activation and protein-protein interactions in a highly specific, spatially resolved, sensitive manner and using a portable high throughput system.

This technology will become critical in patient evaluation both diagnostically and predictively. We have already exploited this technology to demonstrate that the activation of an oncoprotein in breast and colon cancer patients is heterogeneous and correlates with poor disease free survival.

deScription

Tissue based diagnostics remains cornerstone of personalised medicine. However, most of the current methods of analysing protein expression via immunohistochemistry lack adequate quantitation, sensitivity, selectivity and accuracy. Specifically, the detection of endogenous oncoproteins in fixed tumour samples faces several important challenges:

• The specific detection of post-translational modifications such as phosphorylation.

• The simultaneous localisation of these oncoprotein epitopes in preserved tissue architecture iii) the quantitative capture of data in an automated manner.

promoter organization identification

organization name BIOFISIKA (Basque Center for Biophysics)

contact Prof. Banafshé LARIJANI

email [email protected]

phone 0034 946018505

fax -

description of the organization

Public Institution

activity R&D services and technology

markets tackled Oncology, Diagnostic devices, Biotechnology, Biomedicine and Pharmacology

Size 110

FRET Amplified Signal Technology for Biomarker And System Evaluation- (FASTBASE)

18 Technology Offers · HealTH

Page 19: Biotechnology Basque Country

Immunohistochemistry (IHC) is the most readily available method to assess activation of intracellular proteins, however it is limited by the absence of precise quantification and the lack of a standardised scoring system. In addition, it is a “one-site” assay (including fluorophore-based confocal assays) producing results that can only be obtained from measuring the intensity of one label at a time, therefore limiting specificity where epitopes are constrained (eg phosphorylation sites).

To solve the above issues we have used time-resolved FRET for sensitive analysis. FRET detected by fluorescence lifetime imaging microscopy (FLIM) has been proven to be a highly effective method in quantifying the phosphorylation status of intracellular molecules in archived formalin-fixed paraffin-embedded (FFPE) tumour tissue.

Coincidence (two-site) FRET describes the method of simultaneously labelling a single protein on two distinct sites with donor- and acceptorconjugated probes, and detecting the FRET between them. When using twosite FRET, notwithstanding that this method also relies on antigen-antibody immune complexes, energy transfer only occurs when the distance between the two antibodies (for example directed at a specific phospho-site and the protein itself) is less than 10 nm, within the same antigen. Two-site FRET is therefore necessarily more specific.

To date studies of endogenous proteins using FLIM have been limited due to the lack of sensitivity and the additional requirements for extensive characterisation of directly labelled antibodies for each assay developed.

Our method solves these problems by amplifying the signal and doing so in the context of using generic secondary reagents. This assay combines immunofluorescence signal amplification with labelled Fab fragment secondary antibodies in order to maximise sensitivity, specificity.

In parallel, we have developed an imaging platform based on a multiple frequency fluorescence lifetime imaging microscope (mfFLIM) and accompanying software to automatically map a

tissue microarray, acquire FLIM images and distinguish between regions of interest in single cells and tumours, in a high throughput manner with minimal user supervision.

innovative aSpectS

1-This technology detects molecules in a single cell or tissue samples, in particular, protein functional states and protein complexes .

2- This technology permits the quantification of molecular interactions, such as protein-protein interactions in a single cell or tissue sample. Whereas existing technologies can detect co-expression, it cannot quantify dimerisation.

3-Use of FRET (and specially two-site amplified-FRET methods, where the two sites are on the same protein or on different proteins) in combination with an enzyme activation amplification system improves detection of states of molecules in a single cell or tissue samples, such as protein states and a close spatial association of proteins.

main advantageS

The main advantage of this methodology over the current technologies, immunohistochemistry and proximity ligase assays (PLA) are as follows:

Highly specific for in situ detection of post-translational modifications such as phosphorylation as well as endogenous protein-protein interaction

Amplified time resolved FRET which is highly specific and sensitive with the advantage of it being readily adapted to any protein marker

A broad dynamic range, enabling high accuracy and precision

Simultaneous localisation of proteins in preserved tissue architecture

Technology Offers · HealTH 19

Page 20: Biotechnology Basque Country

Acquisition and processing of a large quantity of data in an unbiased automated, high throughput manner

Table summarising the main advantages of amplified-FRET over current technologies

immuno-hiStochemiStry

pla amplified-

fret

Sensitivity + ++ ++++

Selectivity + +++ +++

dynamic range

+ ++ ++++

protein-protein interaction

- ++ ++++

Modified proteins

+ +++ ++++

applicability of the technology

To date this methodology has been mainly exploited in solving problems that have been related to early diagnostics in Cancer .

However, since the main aspect of this methodology is to quantitatively determine endogenous protein-protein interactions (complex formations) and detect activation status of marker proteins then it can also be used in answering questions in pathological states such as diabetes, cardio-vascular disease, diseases related to aging and neurodegenerative pathologies.

Therefore the methodology is not exclusive to answering questions regarding cancer.

current Stage of development

The current methodology is in a prototype stage that will lead to commercialisation. It is complete in its actual stage however it

now needs to be tested in “prospective trials”. The retrospective studies performed by this methodology have shown its advantages over classical immunohistochemistry studies. The next step to conclude is the validation of the technology in order to perform prospective trials in the Spain, uK and uSA.

exploitation of rtd reSultS

To date the development of the methodology has been wholly funded by Cancer Research uK, a registered charity in uK.

intellectual property rightS

In 2013, Cancer Research Technology (UK) filed the patent P26770GB- “Oncoprotein activation in tumours assessed by high throughput coincidence signal amplification-FRET”. As of the 11th March 2014 Cancer Research Technology has filed a PCT – PCT/GB14/050715. The expected publication of the Patent will be 11th September 2014.

Cancer Research Technology is keen on partnering this technology with us.

collaboration type

Our goal is to be the first European company that analyses cancer patient samples using this innovative technology.

Our main focus will be to offer a diagnostic service through the analysis of biopsies from oncology units at hospitals, as well partnering with pharmaceutical companies in clinical trials analysing tumour samples of patients involved in the trials. Moreover we our focus would be to partner with pharmaceutical companies to utilise the novel methodologies as a tool to help development of companion diagnostics. Collaborations/service offerings to Research Institutions will also be considered depending on the project proposal.

20 Technology Offers · HealTH

Page 21: Biotechnology Basque Country

Technology Offers · HealTH 21

Page 22: Biotechnology Basque Country

abStract of technology to exploit

The Biofisika Open Innovation Platform (Biofisika-OIP), an initiative of Biofisika ( the Basque Center for Biophysics), aims to give customized R&D support to Small and Medium Enterprises (SMEs) as well as to Industrial Partners looking to provide and/or strengthen the innovation of their products and services. The Biofisika-OIP can act as an R&D service provider or as your R&D partner in innovation projects requiring strong scientific and technological input. Being focused in all aspects of molecular, cellular and systems biophysics, the Biofisika-OIP can offer a unique expertise to the industry, including Pharmacological, Cosmeceutical, Nutraceutical, and bioenergetic, as well as to Public Institutions. The Biofisika-OIP mission is to assist partners and customers in innovation projects by providing the necessary R&D, in a very tailored and client-wise vision.

deScription

The Biofisika-OIP is structured in 4 technological platforms that provide all the infrastructure needed for carrying the most ambitious R&D projects:

1. molecular and cellular imaging platform:

An Advanced Optic Microscopy unit, offering a singular nanofotonic technology for image analysis that allow the study of quantitative spacetemporal inter- and intramolecular interactions in cells. These studies can be conducted at the advanced Optic Microscopy unit through confocal microscopy and two photon systems, and through the study of the spectroscopic properties of the fluorescent emission at a single pixel (FRET-FLIM y FCS).

promoter organization identification

organization name BIOFISIKA (Basque Center for Biophysics)

contact Dr. Roberto Pascual

email [email protected]

phone 94-6018001

fax -

description of the organization

Public Institution

activity R&D services and technology

markets tackled Biotechnology, Biomedicine, pharmacology and skin care.

Size 110

Biofisika Open Innovation Platform (Biofisika-OIP)

22 Technology Offers · HealTH

Page 23: Biotechnology Basque Country

2. drug discovery and delivery platform:

A High Throughput Screening (HTS) unit to design robust and accurate in vitro screening assays for Drug Discovery and Drug Repurposing projects. The platform posses the equipment to both test single compounds and screen chemical libraries for hit identification and lead validation, as well as for in silico screening. The Drug Discovery and Delivery Platform offer also an Electrophysiology unit and a Quimeric Vaccines Production unit. The Drug Delivery unit exploits both the equipments and the know-how of Biofisika Scientists to design and test new and effective Drug Delivery Systems.

3. protein expression and Structure platform:

This platform offers up to seven Equipment units to produce proteins (up to mg) both in prokaryotic and eukaryotic systems, for solving the protein structure, and characterize their folding and biophysical properties, as well as for protein engineering. The Protein Expression and Structure Platform include the following units:

• Centrifugation and simple concentration Unit

• Microcalorimetric Analysis Unit

• Chromatography Unit

• Image Acquisition, Treatment and Documentation Unit

• Spectroscopy Unit - Crystallography Unit

4. System biophysics platform:

This platform offers a customized protein and systems modeling

service through its potent Bioinformatics unit. This service is mainly oriented to biophysical studies and drug-discovery, but Biofisika-OIP is open to assist in tailored bioinformatic needs and requierements.

innovative aSpectS

The Biofisika-OIP combines a multidisciplinary team of top qualified scientists and technicians arranged in two main Research Lines, offering a wide range of tailored programs and solutions for innovative biotechnological and biomedical projects:

Molecular Biophysics, which encompasses the following areas: Protein Structure and Folding, Membrane Structure and Dynamics, Membrane Transport and Bioenergetics, Molecular Chaperons, Membrane Toxins.

Cellular and Systems Biophysics, which encompasses these areas: Membrane and Cell Fusion, Cellular Excitability and neural Networks, Cellular Imaging and Dynamics, Nanomechanics and Single Molecule, Systems Biology and Medicine.

main advantageS

The Biofisika-OIP offers an innovative scientific and technological strategy that makes this platform a unique R&D provider of innovative knowledge to boost the development and implementation of competitive projects that will result in strengthening the innovation capabilities of industrial and academic partners. The Biofisika-OIP offers a singular and up to date scientific infrastructure that is pivotal to successfully achieve innovative, R&D projects that require quantitative assessment. The cost of the equipments,

Technology Offers · HealTH 23

Page 24: Biotechnology Basque Country

maintenance and the need of highly trained personnel is a handicap for in-house setting by SMEs and industrial and public partners. Thus, outsourcing innovation projects and partnering with the Biofisika-OIP is the more convenient, wise strategy to create and develop innovation, competitiveness and internationalization to your products and projects.

Furthermore, access to the know-how generated by Biofisika scientific groups is an additional advantage for outsourcing your innovation projects to the Biofisika-OIP. The time needed to acquire the know-how and experience in each area is another invaluable asset of Biofisika, which can be accessed through the Biofisika-OIP, to gain a competitive knowledge and advantage for SMEs in their innovative projects.

The Biofisika-OIP technological offer covers a wide range of biophysical techniques, equipments and in house developed assays. All Biofisika Technological Platforms offered are complementary, accordingly the wide range of the R&D activities needed for the successful development of innovation initiatives is guaranteed. Biofisika, through its Biofisika-OIP, is your natural partner for creating innovation and increasing national and international competitiveness for your products and services.

applicability of the technology

The Biofisika-OIP offers the design and development of customer-driven R&D projects, R&D consultancy, and supervision of in-house ongoing R&D initiatives. The Biofisika-OIP gives solutions to your needs by adjusting its R&D capabilities to provide innovative solutions to your requirements. The Biofisika, throuogh its Biofisika-OIP, can be a valued partner for:

• Biotech Companies

• Pharmaceutical Companies

• Nutraceutical Companies

• Cosmeceutical Companies

• Functional Food Companies

• Energy-based companies

• Diagnostic-based companies

• R&D Groups (from research centers, Universities…)

• Foundations

• Clinical departments and hospitals

The Biofisika-OIP will study your proposal and elaborate a tailor-made project to adapt to your needs. The Biofisika-OIP will accommodate the project to your requirements and provide you with your needed innovation. Partnering with BiofisikaOIP makes a lot of R&D sense to be ahead of your competitors.

current Stage of development

Biofisika, the Basque Center for Biophysics, first known as the Biophysics unit, is a joint venture between the uPV/EHu, the CSIC and the Fundación Biofisika Bizkaia (FBB) that was created 12 years ago in the UPV/EHU campus in Leioa. In 2014, Biofisika will move into new state-of-the-art research facilities in the UPV/EHU Scientific Park in Leioa Campus, where the Biofisika-OIP will be fully active. In addition, in 2014 Biofisika has elaborated a Strategic Plan for 2014-2017 where translational biophysics is a major goal and priority. Accordingly, the activities of the Biofisika-OIP will be strengthened, and complemented with the incorporating new research groups that will provide

24 Technology Offers · HealTH

Page 25: Biotechnology Basque Country

complementary skills and knowledge in the fields of molecular and systems neurosciences, and molecular and cellular oncology. Furthermore, scientific infrastructures and human resources will be upgraded as needed, by incorporating the needed skills to offer the best and most efficient R&D services and partnership, and to strengthen the research excellence.

exploitation of rtd reSultS

In addition to provide R&D services to external partners, the Biofisika-OIP also represents the natural channel for the exploitation of in-house generated knowledge and technology, by pursuing agreements with third parties interested in licensing the technology or by encouraging and assisting in the creation of spin-off companies.

intellectual property rightS

Intellectual Property Rights will vary depending on the kind of project and the relationship established between the customer and the Biofisika-OIP. These agreements are always negotiated in a flexible way to ensure the transfer and exploitation of the technologies. In this regard, Biofisika always pursue to be involved in the development process to ensure that the technology reaches the market.

collaboration type

Outsorcing

Joint-development of R&D projects and initiatives

Technology Offers · HealTH 25

Page 26: Biotechnology Basque Country

abStract of technology to exploit

Bioftalmik has developed a tear based “ Point of Care” lab-on-a-chip for specific, sensitive, and non-invasive diagnosis for Dry Eye and Ocular Inflammation.

Our expertise on the study of proteins, metabolites and genes for biomarkers discovery in samples as tears and ocular surface cells together with clinical tests, has implied the development of new tools for diagnostic in the ophthalmology field.

In our molecular diagnostic division, Bioftalmik has developed a PCR-based diagnosis for Limbal Deficiency. This test is highly sensitive and specific, and provides a decision-making tool for surgery and medical treatments such as corneal transplant, limbo transplant, etc.

In the ophthalmic devices development unit, Bioftalmik has developed the “first and unique” one handed disposable intraocular injector designed for ophthalmologists for easier, faster and safer procedure than performed with standard syringes.

deScription

Ocular diseases are main cause of blindness worldwide, loss vision or impairment of visual function, therefore early disease detection is a key factor for control of loss vision and correct medical treatment. The development of kits and tests for diagnosis, prognosis, and therapy based on molecular markers for ocular diseases such as dry eye, blefaritis, other inflammatory ocular diseases, and glaucoma is the core of our research.

The study of non invasive samples such as human tear and cornea/conjunctival cells leads the identification of proteins, metabolites and genes. As one of the body fluid, the tear is a complex secretion containing proteins, mucins, lipids, carbohydrates, hormones, neurotransmitters, electrolytes, etc. The human tear proteome, for example, provides a unique source of specific protein markers of protein patterns that

promoter organization identification

organization name Bioftalmik Applied Research

contact Jon Careaga

email [email protected]

phone +34 944 069 659

fax +34 946 562 379

description of the organization

Biotechnology Company specialized in the ophthalmic field

activity Our main objective is to design, develop and commercialize diagnostic, prognostic and therapeutic systems for eye diseases and biodevices for ophthalmic surgery.

markets tackled Ophthalmology, public and private hospitals, pharmaceutical companies.

Size 7 employees

Tear based diagnostic test for ocular diseases

26 Technology Offers · HealTH

Page 27: Biotechnology Basque Country

may be correlated to more effective diagnosis, prognosis, and response to therapy. With the traditional methods about 100 tear protein have been obtained, however, using proteomics approach it have been possible to find more than 400 proteins. Proteomic techniques have been developed to trigger the progression of the tear studies either in the protein composition and/or concentration of tear and various pathological conditions. The comparable study of healthy and/or disease subjects have lead the discovery of new biomarkers. Additionally, metabolomic studies are carried out for new markers searching.

Similarly, the study of genes and proteins from ocular surface cells using non invasive or minimally invasive samples (ex. Impression cytology) provides relevant tools for molecular PCR- based diagnosis of ocular diseases, and the evaluation of cells response to medicines or treatments. In this way, it is possible to establish the response to and effects on ocular surface cells due topical drugs such as antiglaucomatous, and other therapies.

Disposable devices for ocular surgery, and systems for drug delivery specifically inside of the eye are important systems in treatment of several diseases such as AMD or glaucoma. We offer a new system that allows doctors the intraocular injection using only one hand providing a total control of the eye and facilitating a safer and faster procedure than offered by currently used systems.

innovative aSpectS

The most of ocular diseases are diagnosed on the symptoms referred by the patient, clinical observation by physician, and tests performed by specialised equipment. However, early states of diseases are not easy to detect given that many symptoms are similar in several diseases, thus, the detection of an ocular pathology normally is done when the symptoms are evident, and the damages in cells and vision alteration have happened. Changes in tear proteins have been associated with many ocular or systemic diseases, therefore, the platform for early diagnosis

based on tears analysis constitute an innovative solution for clinical diagnosis.

Similarly, cells of ocular surface respond differently to environment changes and/or application of medicines and treatments. Normally this kind of response is studied in human by traditional PAS staining of epithelial cells that indicate the state of cells, as an innovative approach, we analyse the protein and gene expression of those cells impregnate on the membrane through the impression cytology of corneal/conjunctival epithelial cells.

main advantageS

• Rapid diagnosis in non invasive samples. Using samples such as tears and conea/conjuctiva epithelial cells we detect specific biomarkers for several ocular diseases.

• Analysis and detection in very small samples. Normally the small volume of tears limits its use as source of markers; we have established a platform work that enables diagnosis based on markers expressed in very small volume. Similarly, the impression cytology provides a source of cells which rends a small amount of protein and/or genetic material in which we are able to determine biomarkers for diagnostic.

• Diagnosis of systemic diseases. The tear is considered a source of markers for ocular diseases but also for systemic diseases such as diabetes, cancer, etc. therefore, our diagnosis platform can be employed on other fields of health.

• Personalised therapy. Given that we have specific markers for several diseases, we are working on the development of personalised therapy alternatives based on those markers.

• Customized devices for easier ophthalmic procedures, such us ocular injection.

Technology Offers · HealTH 27

Page 28: Biotechnology Basque Country

applicability of the technology

• Ophthalmology field, in both clinical practice and basical and applied research.

• Pharmaceutical companies focused on development of medicines for ocular diseases,

• Companies that produces contact lens, IOL, topical drugs, eye drops, etc.

• Pharmaceutical companies in general.

• Clinics and hospitals to solve the problems of accurate diagnostic.

current Stage of development

Currently we have some products/services already developed in a commercial stage for diagnostic uses, mainly in public hospitals and clinical. Others are on preclinical and clinical validation and others also in the development of prototype. Some others products are still at a level of research, development and design.

exploitation of rtd reSultS

The most of the products developed are results of our research funded with our funs and also partial supports from Basque and Spanish Government.

intellectual property rightS

We have patented or are in process of patent for all the products and services offered by the company.

collaboration type

We offer contract research development for “Point of Care” non invasive diagnostic and monitoring devices development based in tear film biomarkers from discovery phase to final product development.

28 Technology Offers · HealTH

Page 29: Biotechnology Basque Country

Technology Offers · HealTH 29

Page 30: Biotechnology Basque Country

abStract of technology to exploit

New target was discovered through the study of pathological brain tissue of patients with major depression.

The project aimed to find active molecules that regulate the biological system in which this new target is involved: neurogenesis.

BRAINco validated its hypothesis with the generation of a transgenic animal model that can be considered as a non-clasical model of depression. This transgenic model has also allowed the identification of promising cell signaling pathways affected by the overexpression of the identified target.

The fact that the selected target was a secreted cytokine, has opened the possibility of using it as a biomarker for depression diagnosis and/or patient selection.

deScription

Major depression is a common and sometimes fatal disorder that has lifetime prevalence in excess of 15%. The total annual cost of Depression in Europe is estimated at 118 billion €, which makes depression the costliest brain disorder in Europe.

Current antidepressant treatments are limited by their efficacy and in particular, by the delay in their onset of action. Their activities depend on common mechanisms of action such as selective neurotransmitter reuptake inhibitors or monoamine oxidase inhibitors. New therapies based on novel mechanisms of action are needed to solve these problems.

using genomic and proteomic approaches in human postmortem brain tissues from depressive suicides, BRAINco found altered expression levels of a key cytokine involved in neurogenesis.

The implication of neurogenesis in major depression is widely accepted among the scientific community. In fact, antidepressant drugs produce an increase of neurogenesis in accepted animal models of depression. BRAINco scientists have confirmed the implication of the target on the modulation of neuronal proliferation and differentiation.

promoter organization identification

organization name BRAINco Biopharma S.L.

contact Itsaso Hormaeche, R&D Manager

email [email protected]

phone +34 944 064525

fax +34 944 064526

description of the organization

Privately Held

activity CNS Drug Discovery CNS in vitro diagnosis

markets tackled Drug discovery

Size 5 employees

An innovative target for the detection and treatment of Depression

30 Technology Offers · HealTH

Page 31: Biotechnology Basque Country

The in vivo validation of the role played by the selected target in the etiopathology of Depression has been performed by the generation of a transgenic animal, model that has also allowed the identification of a number of cell signaling pathways and proteins affected by the initial target. Several of these secondary identified targets have already been used by other pharma companies in drug discovery programs for other clinical indications (Lead compounds are commercially available).

On the other hand, the identified target is a secreted cytokine with the potential of becoming a biomarker for the diagnosis and/or patient selection and stratification.

innovative aSpectS

• A novel mechanism of action found altered in the human disease.

• The Target has been validated by the generation of a transgenic animal model.

• The identification of signal transduction pathways altered in the transgenic animal model (and already used for other clinical indications) that could represent innovative targets for the treatment of Major Depression.

• The target is a secreted cytokine that can be measured in the blood.

main advantageS

BRAINco Project Operational Focus:

• Specific structures for specific projects.

• Screening cascade elements is developed together with the ones who will use it.

• Provides operational flexibility.

• Defines development responsibilities, schedules, milestones,

and deliverables.

• Focuses on how the relationship will work (e.g., communication, issue resolution, project reviews).

applicability of the technology

Although today’s treatments for psychiatric disorders are generally safe and effective, they are far from ideal. In addition to the need of administering the drugs for weeks or months before seeing any clinical benefit, side effects are still a serious problem even with the newer medications. And most importantly, about only a third of these patients with these psychiatric diseases, show fully remission with optimized treatment. Consequently, new therapies based on innovative approaches that represent a real qualitative change in pharmacological strategies are urgently needed.

current Stage of development

This program is based on new biological targets and pathways not explored for this disease.

The program is under development/lab tested. A patent has been applied for but not yet granted.

collaboration type

BRAINco would consider different models of partnership from purely financial, to a combination of financial and development collaborations.

We are particularly interested in companies with expertise in CNS diseases, in particular, to medicinal chemistry and preclinical studies.

We are also interested in maintaining open communication line with companies with interest in our project.

Technology Offers · HealTH 31

Page 32: Biotechnology Basque Country

abStract of technology to exploit

New target was discovered through study of pathological tissues of schizophrenic patients.

The project aimed to find active molecules that regulate the biological system in which this new target is involved: the release of neurotransmitters.

BRAINco has discovered and validated a novel target, both at the animal and cellular level, has created the tools necessary for drug discovery and development, and has identified chemical starting points.

deScription

Since 1990s with the emergence of atypical antipsychotics, there have been no major advances in the treatment for schizophrenia. While current drugs modify synaptic transmission acting on dopaminergic system, BRAINco is focusing on the actual process of neurotransmitter release.

BRAINco discovered that proteins involved in exocytosis are differently expressed in the prefrontal cortex of schizophrenic subjects.

Cellular and Biochemical tools as well as an animal model were produced to validate this novel model targeting exocytosis.

BRAINco is also performing a biomarker program in parallel of the drug discovery, in order to develop a strategy for patient selection.

The product will be a tool kit composed of all materials developed for the project, such as stable neuronal cell lines, cellular based assays, assays adapted for High Throughput, Hits, back up, and active molecules that regulate the release of neurotransmitters throughout the modulation of the Exocytosis.

promoter organization identification

organization name BRAINco Biopharma S.L.

contact Itsaso Hormaeche, R&D Manager

email [email protected]

phone +34 944 064525

fax +34 944 064526

description of the organization

Privately Held

activity CNS Drug Discovery CNS in vitro diagnosis

markets tackled Drug discovery

Size 5 employees

Small molecules for the treatment of Schizophrenia

32 Technology Offers · HealTH

Page 33: Biotechnology Basque Country

innovative aSpectS

• A novel mechanism of action found altered in the human disease.

• A very innovative target validated in cellular and animal models.

• Hits able to modulate presynaptic activities.

• Experience in Biomarker discovery.

main advantageS

BRAINco Project Operational Focus:

• Specific structures for specific projects.

• Screening cascade elements is developed together with the ones who will use it.

• Provides operational flexibility.

• Defines development responsibilities, schedules, milestones, and deliverables.

• Focuses on how the relationship will work (e.g., communication, issue resolution, project reviews).

applicability of the technology

Although today’s treatments for psychiatric disorders are generally safe and effective, they are far from ideal. In addition to the need of administering the drugs for weeks or months before seeing any clinical benefit, side effects are still a serious problem even with the newer medications. And most importantly, about only a third of these patients with these psychiatric diseases, show fully

remission with optimized treatment. Consequently, new therapies based on innovative approaches that represent a real qualitative change in pharmacological strategies are urgently needed.

current Stage of development

This program is based on new biological targets and pathways not explored for this disease.

The program is under development/lab tested. A patent has been applied for but not yet granted.

collaboration type

BRAINco would consider different models of partnership from purely financial, to a combination of financial and development collaborations.

We are particularly interested in companies with expertise in CNS diseases, in particular, to medicinal chemistry and preclinical studies.

We are also interested in maintaining open communication line with companies with interest in our project.

Technology Offers · HealTH 33

Page 34: Biotechnology Basque Country

abStract of technology to exploit

We offer a simple, economic and highly sensitive system for pyrogenic agents (endotoxins) detection both in fluids (biological reagents, pharmaceutical products) and in medical devices

deScription

National and international health authorities require that any implantable medical device or parenteral drug undergoes strict analyses to verify that it is free from pyrogenic agents. Pyrogens are molecules of microbial origin which at very low concentrations (femtograms) are detected by the immune system and induce beneficial responses including moderate fever and local inflammation. However, at higher concentrations (micrograms) these molecules trigger acute systemic reactions such as septic shock that often lead to multiorganic failure and death.

Due to its toxicity, stability and prevalence, the most important pyrogen is the lypopolysaccharide (LPS or endotoxin), a molecule present in the surface of gram-negative bacteria. The standard method for LPS detection is the, so called, Limulus Amoebocyte Lysate test or LAL test, which is based on the coagulation cascade of the amebocytes of the horseshoe crab (Limulus polyphemus). This test is laborious, expensive and yields false negative results in the presence of certain organic and inorganic compounds. Furthermore, the low sample volume required for the test limits its sensitivity.

We offer a totally new and innovative method for detecting these pyrogenic agents much more robust than the protocols based on LAL test.

promoter organization identification

organization name CEIT-IK4

contact Gustavo Pego

email [email protected]

phone +34 660 080 652

fax +34 943 213 076

description of the organization

CEIT-IK4 is a non-profit research centre. The Centre’s main aim is to carry out applied industrial research projects through close collaboration with Industrial R&D departments on a contractual basis.

activity Industrial applied research

markets tackled -

Size -

Pyrogenic agents (endotoxins) detection both in fluids (biological reagents, pharmaceutical products) and in medical devices

34 Technology Offers · HealTH

Page 35: Biotechnology Basque Country

innovative aSpectS

Currently, the standard endotoxin detection method is the Limulus Amebocyte Lysate (LAL) test, which is based in the lymph gelification system of the marine chelicerate arthropod known as horseshoe crab (Limulus polyphemus). This system works as a coagulation cascade triggered by endotoxin interaction with the serine-proteases present in the amebocytes of the animal. There are three main LAL test methodologies commercially available: gel-clot, turbidimetric, and chromogenic.

LAL-based tests have the following limitations:

- High price: the cost of these tests ranges between 6 and 60 €/sample depending on the detection method used and the number of samples per assay. These estimations do not take into consideration the cost of the special equipment (chromogenic and turbidimetric methods) and software (turbidimetric) needed to perform the tests. In addition, the cheapest kits (for multiple samples) do not include the pyrogen-free material needed to repeatedly carry out the assays (tubes, microplates plasticware, etc).

- Irregularity: kits usually have significant batch-to-batch variability.

- Instability: The shelf-life of the reagents is very short. For instance, under optimal storage conditions, some of the LAL reagents are not suitable for use one week after reconstitution.

- Lenghty assay times: tests do not yield immediate results but are laborious and require several incubation steps, which prolongs the assay time to at least one hour for the most rapid (and expensive) assays.

- Unreliability: assays are unreliable in the presence of interfering substances and yield either false positive or

negative results. Inhibiting agents include chelators, alcohols, penicillins, tripsin inhibitors, and NaCl above certain concentration, whereas unspecific activators of the LAL cascade comprise compounds such as thrombin, thromboplastin, nucleic acids, Rnases, tripsin, lipoteichoic acids, glucans and peptidoglican, among others. These interferences preclude the use of LAL tests for endotoxin quantification in blood. In addition, results of LAL assays are strongly affected by pH and are only trustworthy when performed at pHs ranging from 6 to 8.

Our device improves most of the characteristics of the standard endotoxin testing assay, the LAL test, therefore the intended device would have to match the sensitivity of this test and simultaneously overcome the limitations describe in the previous paragraphs.

main advantageS

This technology addresses a simple, economic and highly sensitive new system for endotoxin detection both in fluids (biological reagents, pharmaceutical products) and in medical devices. For this purpose, this project will undertake the following tasks:

1. A robust and specific immobilization procedure for endotoxin detection based on patented and specifically designed peptides.

2. A portable device as an enhanced alternative to the LAL method.

Technology Offers · HealTH 35

Page 36: Biotechnology Basque Country

applicability of the technology

As previously described we offer a competitive solution, highly sensitive and reliable, for endotoxin detection in biological reagents, products related to pharmaceutical industry and medical devices.

There are several industrial partners that would greatly benefit from the proposed system. Both parenteral drugs and invasive medical devices are required to undergo pyrogen testing to certify that they are virtually free from endotoxin. Thus, the more accurate and affordable the detection system, the safer the products marketed by the pharmaceutical and biomedical manufacturers.

current Stage of development

The proposed device is already tested in laboratory conditions with synthetic and real samples obtained from some companies that collaborate with us. Now the device is ready for the validation procedure by regulatory agencies.

exploitation of rtd reSultS

The research project was funded by own resources of the university of Navarra.

intellectual property rightS

All the IPR belongs to the groups that are developing the device.

collaboration type

We are looking for industrial partners that could be interested in this device to complete together the validation procedure.

36 Technology Offers · HealTH

Page 37: Biotechnology Basque Country

Technology Offers · HealTH 37

Page 38: Biotechnology Basque Country

abStract of technology to exploit

CEIT-IK4 develops software for biomedical applications. Besides, CEIT-IK4 has capabilities of mechatronic design for designing and manufacturing its own hardware (electronics and mechanics).

deScription

The main research lines are:

• Medical imaging processing from any kind of source (CT, MRI, DTI MRI, fMRI, etc.).

• Based on our knowledge of medical imaging processing and computer graphics, we can develop complex applications of diagnosis, analysis and surgery planning.

•Modelling and simulation of different tissues with different applications:

· Analysis of tissues behaviour

· Development of surgery simulators with the possibility of using haptic devices

• Biomechanics of human motion (impact studies, musculoskeletal human modelling, human motion reconstruction and analysis)

• Control and programming of robots

• Mechanical and electronic design for new medical devices

promoter organization identification

organization name CEIT-IK4

contact Gustavo Pego

email [email protected]

phone +34 660 080 652

fax +34 943 213 076

description of the organization

CEIT-IK4 is a non-profit research centre. The Centre’s main aim is to carry out applied industrial research projects through close collaboration with Industrial R&D departments on a contractual basis.

activity Industrial applied research

markets tackled -

Size -

Software and Hardware for biomedical applications

38 Technology Offers · HealTH

Page 39: Biotechnology Basque Country

innovative aSpectS

In Applied Mechanics department we are able to mix software and hardware knowledge in order to offer more complex products. The combination of multiples disciplines provide us not only with a whole knowledge of the problem but also with the capacity of offering the whole solution.

main advantageS

Thanks to our deep knowledge of software and hardware we can develop complex turnkey solutions for our clients.

applicability of the technology

As we develop turnkey software and hardware, our technology is broadly applicable in any biomedical sector.

current Stage of development

Our software technology of medical imaging and modelling/simulation is very advanced and can be apply immediately into the market (maybe with some little customisation depending on the requirements of the client). Our hardware technology is in a prototype stage.

collaboration type

Industrial applied R&D

Technology Offers · HealTH 39

Page 40: Biotechnology Basque Country

abStract of technology to exploit

Development of sophisticated algorithms to integrate and analyze high-throughput (HT) “omics” data for biomedical and biotechnology research

deScription

Bioinformatics group at CEIT-IK4 is an interdisciplinary team formed by researchers with experience in the field of statistics, mathematical modelling and software development. Since 2001, CEIT-IK4 has worked in genomics, transcriptomics, proteomics and metabolomics data integration and analysis. Currently, the integration of these heterogeneous HT “omics” data with genome-scale biochemical networks is one of their most active research areas.

Current, data processing, analysis and integration are accomplished in the following technologies:

- microarray:

• SNP arrays analysis

· Genotyping

· Copy number variations

• Gene expression analysis

• Splicing analysis

• MicroRNA arrays

- next generation Sequencing:

• DNA-seq analysis

• RNA-seq analysis

promoter organization identification

organization name CEIT-IK4

contact Gustavo Pego

email [email protected]

phone +34 660 080 652

fax +34 943 213 076

description of the organization

CEIT-IK4 is a non-profit research centre. The Centre’s main aim is to carry out applied industrial research projects through close collaboration with Industrial R&D departments on a contractual basis.

activity Industrial applied research

markets tackled -

Size -

Systems Biology

40 Technology Offers · HealTH

Page 41: Biotechnology Basque Country

innovative aSpectS

By definition, the Bioinformatics group at CEIT-IK4 aims to develop novel and sophisticated proprietary algorithms to analyze and interpret HT “omics” data. Our methodologies also go beyond statistical approaches, being the hypotheses generation based on complex network analysis and systems biology at the core of our services, which facilitates experimentalist researchers the maximal exploitation of their generated data.

main advantageS

The outbreak of genome automation and HT “omics” technologies has revolutionized research in biosciences: medicine, biotechnology, etc. This significant progress has generated an enormous quantity of data that demands highly specialized computer tools for its analysis. The translation of “omics” data into practical knowledge is currently a major issue and the Bioinformatics group at CEIT-IK4 provides different solutions to achieve this goal.

applicability of the technology

Our methodology can be applied to different files where high-throughput “omics” data are currently being generated. The collaboration with experimental groups is essential.

- health:

• Identification of drug targets.

• Drug repositioning.

• Clinical Biomarkers.

- biotechnology:

• Novel biosynthesis and degradation pathways of interest

• Efficient strain optimization

• Media design

• Bacterial communities

current Stage of development

- Services of microarrays and RNA-seq data analyses are currently developed at commercial stage.

- Search for drug targets, drug repositioning and clinical biomarkers are in prototype stage.

- Services of DNA-seq data are currently under development.

- Services for biotechnology are currently at a more theoretical stage.

exploitation of rtd reSultS

These services come from regional and national projects, as well as our own resources.

intellectual property rightS

CEIT owns proprietary algorithms for these services.

collaboration type

Open to all type of collaboration with industry, research centres or universities.

Technology Offers · HealTH 41

Page 42: Biotechnology Basque Country

abStract of technology to exploit

CIDETEC-IK4 is developing different research lines for both biomedical and pharmaceutical applications. Those lines are summarized as follows:

• Synthesis of colloidal systems: IK4-CIDETEC synthe-sizes polymer nanoparticles of a wide range of sizes and materials. Small particles < 20 nm in size, submicromiter pH-responsive waterborne colloidal microgels or biodegrad-able nanogels.

• hydrogels: Owner technology of a new family of injectable hydrogels.

• bioactive surfaces: Highly hydrophilic coatings based on hydrogels with tailored properties. In addition, IK4-CIDETEC is expert in several electrochemical technologies with application in the biomedical field: i) Anodization of biocompatible metals, ii) Electrophoretic deposition of biomolecules and ceramic coatings.

• Electrochemical biosensors: Development of biosensors based scalable low cost plastic supports applicable for health, agriculture and biotechnological applications.

deScription

IK4-CIDETEC is specialized in the synthesis and characterization of biomaterials.

Starting from a single polymer chain, the biomaterials group generates multifunctional colloidal systems of nanometric size (<20nm), produced in water by an easily scalable process for drug-delivery or imaging applications.

Other interesting systems consist on submicrometer pH-responsive waterborne colloidal nano/microgels which can swell/Deswell upon pH changes for drug delivery as vehicle or

promoter organization identification

organization name IK4-CIDETEC

contact Dr. Iraida Loinaz

email [email protected]

phone +34 943 309022

fax +34 943 309136

description of the organization

IK4-CIDETEC, Centre for Electrochemical Technologies, was created in 1997 as a non-profit Foundation whose mission is to serve the industry to enhance its competitiveness through the implementation of innovative procedures and products.

IK4-CIDETEC addresses all electrochemical technologies mainly from an applied research point of view. Its experience and “know-how” covers three main areas of activity: Energy (Batteries, Fuel Cells and Materials for Energy systems), Surface Finishing (Ceramic and Metallic Coatings, Surface Processing) and Materials (Nanomaterials, Biomaterials and Sensors).

activity Industrial applied research in the field of biomaterials.

markets tackled Biotechnology, biomedical, pharmaceutical and food.

Size IK4-CIDETEC had an annual turnover of 8,8M€ in 2012 and at the present time employs a highly qualified staff of 126 people (53 PhD included).

Biomaterials Synthesis and Electrochemistry

42 Technology Offers · HealTH

Page 43: Biotechnology Basque Country

tissue engineering as injectable gels.

Another field of interest is the generation of hydrogels. IK4-CIDETEC is owner of a new family of injectable hydrogels with astounding and shear thickening properties to be used as medical device or injectable scaffold in regenerative medicine.

IK4-CIDETEC is a Research Center experienced in surface modification and characterisation. Electrochemical and self assembling techniques are evaluated to obtain bioactive coatings over wide range of substrates (metals, glasses, plastics,…) with application in prosthetics, pharmaceutics and biotechnology. The objective is to obtain biomimetic and bioactive surfaces and some technologies have being already optimised to obtain coatings based on titanium anodizing, ceramic electrophoresis.

In the last years, IK4-CIDETEC has been applying their knowledge in the field of hydrogels to generate highly hydrophilic polymer coated medical implants to improve biocompatibility, lubrication, reduction of the wear in prosthesis or even to use as photoactive surface with application in the development of microarrays.

IK4-CIDETEC has proven expertise in the research and development of electrochemical (bio)sensors, based on screen-printing technology, for the detection of analytes in clinical, environmental and food fields. The capacity for the design and fabrication of our screen-printing electrodes allows the customization for specific applications.

innovative aSpectS

IK4-CIDETE focuses applied research into industrial applications. This gives the opportunity to develop high quality research and innovative solutions.

• polymer nps: Polymer nanoparticles based on a single chain collapse to tailor low polydisperse, and very small polymer nanoparticles below 20 nm in size.

• microgels: pH-responsive microgels respond to external

pH changes in a accurate way, and can be easily obtained and scalable. Introducing a biodegradable monomers, biodegradable systems can be synthesized.

• hydrogels: The technology is applicable to a wide range of polymers (synthetic and natural polymers) and is based on supramolecular cross-linking.

• highly hydrophilic polymer coatings: IK4-CIDETEC has generated polymer coatings that could reduce 10 times the wear in prosthesis.

• biosensors: Cheap, highly sensitive and portable technology.

main advantageS

• polymer nanoparticles – Single Chain Collapse route is applicable to a wide range of polymers and it is being applied for the synthesis of multifunctional particles reaching particles below 10 nm size. This technology allows the fabrication of NPs with polydispersities below 1.1 in order to reach optimal solutions in applications like drug delivery and molecular imaging.

• hydrogels – The technology is applicable to a wide range of polymers (synthetic and natural polymers). By combination of their two components the hydrogels form in seconds and there injectable. They have self-healing properties, after breaking in pieces, they regenerate their mechanical properties. Those systems show shear thickening properties, and their mechanical properties can be adjustable.

• Surface biofunctionalization - Electrochemical Technologies offer scalable, robust, ad-hoc coating design for biomedical field. The highly hydrophilic coatings with reduced friction coef-ficient that could reduce wear in prosthesis ten times. It could also include multifunctionality and control biofouling or even prevent from infections.

Technology Offers · HealTH 43

Page 44: Biotechnology Basque Country

• electrochemical biosensors – IK4-CIDETEC builds their own plastic sensor platforms by low cost screen printing processes. This technology has been optimized in terms of sensibility and selectivity. IK4-CIDETEC capacities cover all the value chain from design until integration. In hence offers reduced time-to-market products.

applicability of the technology

• pharma and cosmetics: Multifucitonal NPs for therapy and imaging in cancer. Drug nanoformulation for topical doses (inhalatior, skin). Microgels /capsules for targeted drug delivery. Nanoformulation of antibiotics. Hydrogels. Electrochemical biosensors for diagnosis.

• biotech: Injectable hydrogels for tissue engineering. Stimuli responsive microgels for enzyme encapsulation. Photoactive surfaces for MALDI analysis. Controlled release of growth factor.

• medical devices: Highly biocompatible bioactive coatings. Coatings for implants to reduce friction and wear. Antifouling coatings. Antibacterial coatings. Injectable hydrogels. Anodized and biofunctional coatings. Ceramic coatings prepared by electrophoresis.

• other: Chemical Industry: Antifouling coatings. Food: Neutraceutical encapsulation. Biosensors. Agriculture: Gel formulations.

current Stage of development

The technologies offered in the biomedical field have been optimised at lab scale and they are being oriented to real industrial applications under the frame of different private contracts with industrial companies.

intellectual property rightS

The intellectual property rights are designed and agreed for each specific collaboration.

collaboration type

IK4-CIDETEC collaborates with other technology agents (university, Laboratories, Research Centers,...) in the frame of different Projects in order to develop novel technologies for further industrial competitive and high added value applications. In the case of industrial companies, the collaborations are mainly made under private and confidential contracts.

44 Technology Offers · HealTH

Page 45: Biotechnology Basque Country

Technology Offers · HealTH 45

Page 46: Biotechnology Basque Country

abStract of technology to exploit

Uniquely capable of offering the complete package of consultancy and hands-on support for drug development from molecule to regulatory approval and from titter to the adult and the child. The Dynakin group comprises a GLP biolab, a clinical trial CRO (Clinical Research Organization), a full MBDD (model based drug development) strategic consultant team and a regulatory affairs advisor team with direct experience in complex applications. The Dynakin group also covers information technology for custom software for industrial drug development and for clinical post marketing (DynaPRED®).

The Dynakin business model is proven by being one of the fastest growing companies in the sector in Europe. Over 80% of our (repeat!) clients are based in Germany, Switzerland or the UK.

deScription

Dynakin’s services cover all aspects of development: GLP wet lab, some in vitro and cell line testing then also population pharmacokinetic (PK), pharmacodynamic (PD) (PK/PD) analysis, regulatory standard Modeling & Simulation, clinical trial protocol design, preparation and CT execution and regulatory report preparation and presentation to the agencies.

Dynakin’s Drug Modeling & Consulting (DMC) group offers a wide range of strategic advice services based on extensive expertise in drug development strategy and regulatory aspects and international class expertise in MBDD via M&S (modelling and simulation) technologies. The combination of our regulatory and CT design expertise and MBDD improve rationalization of strategic decision making, reducing development costs and candidate attrition. The professional expertise of Dynakin in the modelling & simulation field covers complete study design and

promoter organization identification

organization name Dynakin, S.L.

contact Nerea Leal

email [email protected]

phone +34 944 04 55 04

fax +34 946 55 94 63

description of the organization

Private biotechnological company

activity trategic Decision Advisors Drug for Drug Development and Start up

markets tackled Germany, Switzerland, UK, Spain

Size 20

Dynakin, strategic decision assistance for drug development via regulatory, Modeling & Simulation, Clinical Trial design and execution and GLP Biolab departments in four central European countries

46 Technology Offers · HealTH

Page 47: Biotechnology Basque Country

optimization, assistance in protocol preparation, final reporting and regulatory submission. DMC has extensive experience in the design, execution, MBDD consulting and regulatory chaperon related with these aspects:

• Protein mapping

• Pre-Clinical

• FTIM

• Clinical

• Clinical Trial

• Bioequivalence

• Pharmacokinetic, Pharmacodynamics

• Disease progression

• Competitor therapeutic margin

• Logistics, Quality, Vigilance

• Biostatistics

• Pharmacoeconomics

• PK/PD Analysis and Modeling

• Medical Reporting

• Regulatory Reporting

• Regulatory Presentation

• Pediatric Investigation Plan

Dynakin’s products include:

Web based applications for facilitating marketing and clinical (post marketing) use (DynaPRED® product line).

Custom made software for high end industrial development that includes data management and modelling and simulation.

Commercial standard metadata bases directly applicable to decision

making on specific therapeutic areas for comparators and disease progression.

In addition, all our services and most of our products are flexibly adjusted to the clients need in more dimensions (cost, time) than by any other similar organization.

innovative aSpectS

Dynakin is unique in having tried a risky model of bringing together under the same roof a very wide range of international experts in drug development while investing heavily in industrial development support infrastructure (GLP Biolab). Throughout our own growth, a managerial focus was in avoiding the collateral of a heavy overhead structure thus now Dynakin offers maximal productivity at the lowest time and money cost for the client.

The outcome is a success for this business of model of having under the same roof from pharmacologists to regulators to physicists and computer scientists (all PhD’s) and from high tech wet lab to a world class consultation team bound by the same internal vision of our clients being able to rely confidently and completely on our assistance. Most of our clients are word of mouth or repeat from major first class industrial (pharma) nations in Europe. The whole is complemented by a line of product supporting pharmacoeconomic based marketing.

main advantageS

At this point in time there is no single pharmaceutical company independent of size that does not request at some point external expertise in decision making. In no other industry such wide discipline matching of top class expertise is required to have a chance to approve a drug while surviving financially.

Technology Offers · HealTH 47

Page 48: Biotechnology Basque Country

Far more so for virtual or start up companies who cannot and need not acquire all the expertise required for drug development.

Dynakin can resource any or all development tasks for our clients flexibly and at the pace required by the client and not at ours!

applicability of the technology

Dynakin collaborates with client expert teams focusing solely on a specific aspect (Modelling & Simulation, Regulatory preparation, clinical trial design, GLP lab) or with is fully qualified by the client to complement that entire effort or a combination or all of the above tasks for development. Our applicability lies in our flexibility!

current Stage of development

All Dynakin services are fully mature and tested. Our products undergo continues improvement as we are also a “commercial research organization”. Over 30% of Dynakin’s budget is invested keeping our products and services in the forefront of the rapidly changing pharmaceutical development field.

The DynaPRED® series of products is currently under nearly complete rebuild from the ground up to provide a set of stand-alone user- friendly web-based tools for the clinician at bed side for adults and children to neonates. The products, constituting an industrial secret of the company, integrate Dynakin’s own therapeutic area expertise to guide individualized patient dosing decision. This second generation of routines (end of 2011) will be easily integrated into programmable dosing pumps.

exploitation of rtd reSultS

The majority of the DynaPRED® line (specific therapeutic areas) is Dynakin owned and developed. Parts of the extended application (neonates, pumps) are co-financed and owned by public and private entities.

intellectual property rightS

Trade secret.

collaboration type

Dynakin is interested in collaborating with industry partners in life sciences and to offer their services to the pharmaceutical laboratories.

48 Technology Offers · HealTH

Page 49: Biotechnology Basque Country

Technology Offers · HealTH 49

Page 50: Biotechnology Basque Country

abStract of technology to exploit

Our scientific and technical expertise in the fields of molecular biology, microbiology, immunochemistry and enzymology enable us to develop innovative biological assay-based biodetection systems (including lateral flow strips or the technique known as immuno-qPCR) and to implement them for use as analytical tools with numerous applications in human, animal and environmental health and food traceability and safety.

Our activities also cover strategies for optimising and characterising immobilisation processes for biorecognition molecules on surfaces and the development of biodetection systems which may require the modification and/or functionalisation of biorecognition molecules. Likewise, we aim to incorporate biological recognition mechanisms into devices.

Our current goal is to develop biosensors. These devices combine the biological sensor (antibodies, enzymes, nucleic acids, amongst others), the signal transducer and the detector into a single system. Such devices have numerous biodetection applications and offer advantages such as high specificity and sensitivity, shorter analysis times, portability, and the possibility for automation.

deScription

Development of biodetection systems:

• RT-PCR

• Inmuno-qPCR

• Surface plasmon resonance (SPR)

• Lateral flow with fluorescent microspheres

• High Resolution melting (HRM)

Validation of sensor devices: microPCR, magnetic sensors, electrochemical sensors.

Identification of target molecules or analytes of interest.

In Vitro Diagnostic tests promoter organization identification

organization name GAIKER-IK4

contact Maitane Ipiñazar

email [email protected]

phone +34 600 23 23

fax +34 600 23 24

description of the organization

GAIKER-IK4 Technology Centre is a non-profit foundation devoted to the up-take of own knowledge and to the development of new technologies that are later transferred to customers coming from sectors such as the Pharmaceutical Industry, Chemical Industry, Human and Animal Health, Engineering and Consultancy Firms, Public Administrations, Automotive Industries, Construction, Packing and Packaging, and Home Appliances, amongst others.

From 1985, the Centre has carried out more than 1.400 R&D Projects related to its Knowledge Areas: Biotechnology, Environment and Recycling and Plastics and Composites. Besides its activity in R&D, GAIKER-IK4 offers to its customers Advisory and Technical Assistance Services, Certified Analysis and Tests and Official Recognition of Products, as well as Training and Dissemination Service.

GAIKER-IK4 was awarded in 2008 by the European Foundation for Quality Management (EFQM) with the “Prize Winner” for the best European organisation in “Management for Process and Facts”. GAIKER-IK4 also has certifications such as ISO 9001, GLP, ISO 14001, EMAS, which show its strong commitment with quality and continuous improvement.

(www.gaiker.es)

activity R&D

markets tackled Pharmaceutical, Cosmetics, Chemical, Food

Size 117

50 Technology Offers · HealTH

Page 51: Biotechnology Basque Country

Identification of antigen markers using bioinformatic-based tools.

Identification and characterisation of target molecules of diagnostic/prognostic interest in real-life samples (saliva, urine, tears, serum…).

Combinatorial biochemistry-based molecule development.

• Aptamer development

• Peptide development (phage display)

Antibody development

• Polyclonal (pseudo-monoclonal) antibody development

Surface immobilisation processes for biorecognition molecules

• Immobilisation of biorecognition molecules on gold

• Immobilisation of biorecognition molecules on microsphere surface (carboxyl, silica, polystyrene…)

innovative aSpectS

The biosensor-devices combine into a single system the biological recognition bio-elements with the signal transducer and the detector. These devices have numerous biodetection applications and offer advantages such as high specificity and sensitivity, shorter analysis times, portability and the possibility for automation.

GAIKER´s key strength is the availability to adapt to the customer needs and proactive thinking on behalf of customer, efficient R&D project management and on-time deliveries.

main advantageS

We count on our high qualified personnel working on different biological specialties as cellular, biochemical, molecular, genetic, microbiological, genomic and proteomic technologies in our ultimate laboratories with the latest vanguard equipment.

Our main equipment:

• SURFACE PLASMON RESONANCE (ProteOn XPR36 Protein Interaction Array System)

• DNA MICROARRAY SCANNER (AGILENT G2565CA)

• RNA/DNA EXTRACTION ROBOT (QIACUBE)

• PROTEOMIC PLATFORM

• RT-PCR

• FLUORESCE MICROSCOPY AXIO OBSERVER Z1

• CONFOCAL MICROSCOPY. ZEISS LSM 700

• BIODOT

• AKTA EXPLORER

• BIODOT- INMUNOCHROMATOGRAFY STRIP TEST PRODUC-TION

applicability of the technology

Pharmaceutical

• Biotech

• Clinics/Hospitals

• Medical devices and medical equipment

• Environment enterprises

• Agro-food industry

• Analytical testing laboratories

current Stage of development

R&D

collaboration type

Pharmaceutical, Biotech industry, medical devices and medical equipment industry, public and private hospitals, environmental and agro-food industries, academia and R&D centres.

Technology Offers · HealTH 51

Page 52: Biotechnology Basque Country

abStract of technology to exploit

The Biotechnology Division performs Good Laboratory Practice (GLP)-certified in vitro studies during the toxicology, efficacy and pharmacokinetic testing of pharmaceuticals, nutraceuticals and cosmetics. We also apply genomic- and proteomic-based technologies to pharmacogenomic, molecular-diagnosis and genetic-susceptibility assessments.

deScription

adme –pk

In Vitro permeability:

• PAMPA

• CACO-2 permeability

• MDCK permeability

• In vitro transporter assays

· ATPase assays

· Vesicular transport assays

In vitro metabolism:

• Drug-drug interaction assays

· Cytochrome P450 inhibition:

- IC50 determination

- Ki determination

· Cytochrome P450 induction

· Cytochrome P450 isoforms identification

· P-glycoprotein inhibition

• Cytochrome P450 reaction phenotyping

• Microsomal stability

Preclinical in vitro services promoter organization identification

organization name GAIKER-IK4

contact Maitane Ipiñazar

email [email protected]

phone +34 600 23 23

fax +34 600 23 24

description of the organization

GAIKER-IK4 Technology Centre is a non-profit foundation devoted to the up-take of own knowledge and to the development of new technologies that are later transferred to customers coming from sectors such as the Pharmaceutical Industry, Chemical Industry, Human and Animal Health, Engineering and Consultancy Firms, Public Administrations, Automotive Industries, Construction, Packing and Packaging, and Home Appliances, amongst others.

From 1985, the Centre has carried out more than 1.400 R&D Projects related to its Knowledge Areas: Biotechnology, Environment and Recycling and Plastics and Composites. Besides its activity in R&D, GAIKER-IK4 offers to its customers Advisory and Technical Assistance Services, Certified Analysis and Tests and Official Recognition of Products, as well as Training and Dissemination Service.

GAIKER-IK4 was awarded in 2008 by the European Foundation for Quality Management (EFQM) with the “Prize Winner” for the best European organisation in “Management for Process and Facts”. GAIKER-IK4 also has certifications such as ISO 9001, GLP, ISO 14001, EMAS, which show its strong commitment with quality and continuous improvement.

(www.gaiker.es)

activity R&D

markets tackled Pharmaceutical, Cosmetics, Chemical, Food

Size 117

52 Technology Offers · HealTH

Page 53: Biotechnology Basque Country

• Hepatocyte stability

• Metabolities profiling and identification

• Protein binding

• Plasma protein binding

toxicology ServiceS

Cytotoxicity

• MTT

• XTT

• Neutral red

• Alamar Blue

• LDH

• MTS

Cellular function analysis

• Mitochondrial functionality

• Oxidative stress

• Intracellular glutathione

• Calcium flux

• Lipid stability

• Signals transduction

• Intracellular pH

Genotoxicity

• Ames test (OECD TG 471)

• In vitro mammalian cell gene mutation test (OECD TG 476)

• In vitro mammalian cell micronucleus test (OECD 487)

Organ toxicity

• Hepatotoxicity

• Cardiotoxicity

• Skin toxicity

• Ocular toxicity

Toxicological gene regulation

• Toxicogenomics

• qRT-PCR

cellular activity

Proliferation

Migration

innovative aSpectS

Our high qualified scientists work on different biological specialties as cellular, biochemical, molecular, genetic, microbiological, genomic and proteomic technologies in our ultimate laboratories.

Our main equipment:

uPLC MS/MS

HPLC/DAD/MS

HPLC/FL

GC/MS

FPLC

SuRFACE PLASMON RESONANCE (ProteOn XPR36 Protein Interaction Array System)

Technology Offers · HealTH 53

Page 54: Biotechnology Basque Country

CYTOMICS FC 500-MC FLOW CYTOMETRY

FLuORESCE MICROSCOPY AXIO OBSERVER Z1

CONFOCAL MICROSCOPY. ZEISS LSM 700

CELL CuLTuRE BIOBANK

DNA MICROARRAY SCANNER (AGILENT G2565CA)

RNA/DNA EXTRACTION ROBOT (QIACuBE)

PROTEOMIC PLATFORM

q-PCR, HRM-PCR

main advantageS

GAIKER IK4 complies with current requirements for GLP while maintaining efficiency. We count on our high qualified personnel and latest vanguard equipment to develop customized assays for cosmetics, pharmaceuticals, medical devices and functional food assessments.

GAIKER´s key strength is the availability to adapt to the customer needs and proactive thinking on behalf of customer, efficient R&D project management and on-time deliveries.

• DNA MICROARRAY SCANNER (AGILENT G2565CA)

• RNA/DNA EXTRACTION ROBOT (QIACUBE)

• PROTEOMIC PLATFORM

• RT-PCR

• FLUORESCE MICROSCOPY AXIO OBSERVER Z1

• CONFOCAL MICROSCOPY. ZEISS LSM 700

• BIODOT

• AKTA EXPLORER

• BIODOT- INMUNOCHROMATOGRAFY STRIP TEST PRODUC-TION

applicability of the technology

• Pharmaceutical

• Biotech

• Clinics/Hospitals

• Medical devices and medical equipment

• Environment enterprises

• Agro-food industry

• Analytical testing laboratories

current Stage of development

R&D

collaboration type

Pharmaceutical, Biotech industry, medical devices and medical equipment industry, public and private hospitals, environmental and agro-food industries, academia and R&D centres.

54 Technology Offers · HealTH

Page 55: Biotechnology Basque Country

Technology Offers · HealTH 55

Page 56: Biotechnology Basque Country

abStract of technology to exploit

cleaning and detergency

In this field of application we develop technologies extendable to industries for the production of biological agents, essentially micro-organisms and enzymes, with cleaning and detergency activities. We select the agents that provide the greatest yield for different environmental conditions of temperature, ph, nutrients, toxic elements, light, etc.

description

Our lines of technological activity are:

• Optimal determination of the activity of industrial enzymes and their conditions of performance and use. Enzymatic activities: proteolytic, lipolytic, amyolytic, cellulolytic.

• Optimization of enzyme performance conditions with a view to appropriate formulation of the end product. Compatibility of biological product formulations (enzymes and microorganisms).

• Search for super-degrading microorganisms by means of the exhaustive and systematic screening of microorganisms in different habitats where the desired activities are high: lipolytics, proteolytics, amylolytics, cellulolytics, or more specific activities such as keratinolytics (for unblocking products) or pesticide degrading.

• Cloning of microorganisms that produce modified enzymes in such a way that they act in concentrations other than native and are therefore more favourable for formulation of the product.

Industrial biotechnology promoter organization identification

organization name GAIKER-IK4

contact Maitane Ipiñazar

email [email protected]

phone +34 600 23 23

fax +34 600 23 24

description of the organization

GAIKER-IK4 Technology Centre is a non-profit foundation devoted to the up-take of own knowledge and to the development of new technologies that are later transferred to customers coming from sectors such as the Pharmaceutical Industry, Chemical Industry, Human and Animal Health, Engineering and Consultancy Firms, Public Administrations, Automotive Industries, Construction, Packing and Packaging, and Home Appliances, amongst others.

From 1985, the Centre has carried out more than 1.400 R&D Projects related to its Knowledge Areas: Biotechnology, Environment and Recycling and Plastics and Composites. Besides its activity in R&D, GAIKER-IK4 offers to its customers Advisory and Technical Assistance Services, Certified Analysis and Tests and Official Recognition of Products, as well as Training and Dissemination Service.

GAIKER-IK4 was awarded in 2008 by the European Foundation for Quality Management (EFQM) with the “Prize Winner” for the best European organisation in “Management for Process and Facts”. GAIKER-IK4 also has certifications such as ISO 9001, GLP, ISO 14001, EMAS, which show its strong commitment with quality and continuous improvement.

(www.gaiker.es)

activity R&D

markets tackled Pharmaceutical, Cosmetics, Chemical, Food

Size 117

56 Technology Offers · HealTH

Page 57: Biotechnology Basque Country

• Cloning of microorganisms that produce interesting enzymes, including microorganisms that cannot be cultivated.

• Search for and isolation of the enzymatic activities of non-cultivable organisms from metagenomic libraries. Screening of multiple activities based on said libraries.

• Improved productivity: microorganisms or conditions of enzyme activity (e.g. enzymes that work in cold temperatures) by means of directed or random mutation.

• Fermentation on a 5-litre scale to obtain crude enzyme extracts.

• Support in the industrial application of enzymes and microorganisms.

• Determination of the comparative effectiveness of the end products obtained, formulated with enzymes or microorganisms.

agricultural chemiStry

In the field of industrial microbiology applied to the agricultural chemistry sector, we seek to substitute chemical compounds with biological agents that offer an identical function and reduce environmental impact. We also develop new biopesticides and fertilisers based on different protein hydrolysates. In the field of animal nutrition, we collaborate in developing animal feed.

description:

Our lines of technological activity are:

• Obtaining of microorganisms that secrete an antagonistic component against pathogenic organisms to achieve the formulation of biological products for agricultural or environmental application.

• Identification of the active substances (enzymes, peptides…) of antagonistic microorganisms used in biological plague control.

• Obtaining of active substances for biological control by means of genetic engineering for industrial production.

• Optimisation of the conditions of culture of microorganisms for their industrial use in producing biopesticides.

• Quality control of the end product. Life span study.

• Obtaining of protein hydrolysates from enzyme technology for their use in fertilisers (easily assimilated N source) and of more easily assimilated animal feed.

• Fermentation on a 5-litre scale to obtain crude enzyme extracts.

• Support in the industrial application of enzymes and microorganisms.

agrifood

The biological technologies applied in the food and agriculture sector are aimed at ensuring quality, traceability and guaranteeing species, and at obtaining and establishing bioactive, prebiotic and probiotic properties. We combine microbiological and biochemical

Technology Offers · HealTH 57

Page 58: Biotechnology Basque Country

techniques, molecular biology and cellular cultures in order to achieve complete development, from the identification of an asset, its production and evaluation of functionalities

description:

Our lines of technological activity are:

• Obtaining protein hydrolysates from enzyme technology with specific properties: emulsifiers, flavourings.

• Characterisation of protein hydrolysates.

• Determination of bioactivity in protein hydrolysates and peptide fractionations obtained by enzyme technology with cellular cultures.

• Development of new processes that use enzymes and/or microorganisms.

• Determination of bioactive peptide activity in animal origin hydrolysates. Evaluation of different biological activities in in vitro systems.

• Isolation of potentially probiotic microorganisms for animal feed. Evaluation of prebiotic and probiotic activities. Formulation of these microorganisms in the end feed. Development of systems for genetic characterisation and viability control in the end product.

• Determination of biological polluting agents (presence of DNA of different species) in products with high hydrolysis, such as enzymatic gelatins and hydrolysates.

innovative aSpectS

We seek to substitute chemical compounds with biological agents that offer an identical function and reduce environmental impact.

We valorise food products and by-products searching for functional ingredients, making their purification and electivity evaluations.

main advantageS

The reduction of environmental impact.

Obtaining a sustainable, effective, biological product for industrial and agricultural applications

applicability of the technology

• Biotech

• Pharmaceutical

• Chemical

• Environment enterprises

• Agro-food industry

current Stage of development

We have the knowhow for developing the described biological agents.

collaboration type

Development of products and processes for enterprises, pharmacy, biotech, chemical environment and agro-food industries.

Collaboration with the mentioned companies and with public and private R&D organisms.

58 Technology Offers · HealTH

Page 59: Biotechnology Basque Country

Technology Offers · HealTH 59

Page 60: Biotechnology Basque Country

abStract of technology to exploit

HISTOCELL is certified as GMP producer of cell therapy products by the Spanish Medicines Agency (equivalent to EMEA). Our company is interested in the transfer of this technology to other countries in collaboration with local partners. We are also capable of producing GMP cell therapy products as condrocites, fibroblasts or adipose derived mesechimal stem cells (ADMSC) for hospitals, biotech or pharmaceutical companies which have the authorisation for patients use of these products.

deScription

Our company is an authorised GMP cell therapy producer. We have a clean room of 65 square meters capable of treating 200 patients samples per year. The technology is the GMP production in our clean room of cell therapy final or intermediate products. Nowadays, HISTOCELL is expanding condrocytes and adipose derived mesenchymal stem cells, but we are ready to produce other cellular products in our GMP facilities.

innovative aSpectS

Regenerative medicine is a very innovative area where the first clinical trials are nowadays going on. Therefore, there are very few companies specialised and with the adequate personnel and facilities for GMP production of the final or intermediate cellular products.

main advantageS

The GMP production of cell therapy products requires a huge investment in the facilities, technology, regulatory issues and

promoter organization identification

organization name HISTOCELL

contact Julio Font

email [email protected]

phone +34 94 6567900

fax +34 94 4036999

description of the organization

Biotechnology company for cell therapy

activity Our company is focused on the research, development and production of new cell therapy and tissue engineering products for regenerative medicine

markets tackled Public and private hospitals, pharmaceutical companies, biotech companies.

Size 31 employees

GMP production of different cell therapy products

60 Technology Offers · HealTH

Page 61: Biotechnology Basque Country

highly specialised personnel. The main advantage of working with HISTOCELL is to avoid this huge and time-consuming investment in customers not specialised in producing but interested in patients application of adult stem cells. Our company has both the capabilities for GMP production of cell therapy products and the know-how for this technology application and transfer.

applicability of the technology

The cell therapy products are nowadays medicines so it could only be used in patients if they are registered under the EMEA or FDA, or they could be used under the frame of clinical assays both commercial or non-commercial.

current Stage of development

HISTOCELL is certified as GMP producer of cell therapy products by the Spanish Medicines Agency (equivalent to EMEA) so the company is ready for GMP production of cell therapy products.

intellectual property rightS

Not relevant for the GMP production, but it should be discussed in each case.

collaboration type

Contracting the GMP production of cell therapy products.

Collaborative agreement with local partners for the technology transfer of this technology to other countries.

Technology Offers · HealTH 61

Page 62: Biotechnology Basque Country

abStract of technology to exploit

Histocell’s CTTS Technology™ is a novel cell and tissue shipping technology based on an innovative media, which enables the shipping of a wide range of cell types at room temperature. The main application of this technology is the development of ready-to-use cell based assay models for research purposes.

deScription

Histocell CTTS Technology™ is based on an innovative shipping media with excellent cell and tissue preservation properties, together with a detailed procedure for cell culture arrangement, shipping and recovery at destination. The novel shipping media consists of a mixture of low melting point agarose and agarase in low concentrations, which together form a stable gel to embed or cover the cell culture during transportation. Agarose is a thermally reversible polysaccharide which is hydrolyzed by the agarase in the mixture when this is subject to a temperature of 37ºC, which coincides with the melting point of the agarose. These unique properties combined allow the mixture to be maintained in an adequate semisolid state during transportation at room temperature in order to ensure optimal cell survival rates. upon arrival at destination, the agarase is activated through a simple incubation process at 37ºC, initiating a full and homogeneous digestion of the agarose. The resulting liquid mixture is easily removed and replaced with culture media, rendering the platform ready for the performance of the adequate assays.

innovative aSpectS

The main innovative aspect of the CTTS Technology™ is in its shipping media, a unique combination of low melting point agarose and agarase in low concentrations, which at room temperature form a stable gel protecting the culture throughout a transportation time frame of up to one week. Delivery of

promoter organization identification

organization name HISTOCELL

contact Julio Font

email [email protected]

phone +34 94 6567900

fax +34 94 4036999

description of the organization

Biotechnology company for cell therapy

activity Our company is focused on the research, development and production of new cell therapy and tissue engineering products for regenerative medicine

markets tackled Public and private hospitals, pharmaceutical companies, biotech companies.

Size 31 employees

Novel cell and tissue storage and shipping technology

62 Technology Offers · HealTH

Page 63: Biotechnology Basque Country

fresh cells in optimal conditions is now possible, as opposed to cryopreservation, a conventional cell shipping technique which has been confirmed to negatively affect cell integrity and which involves a critical culture recovery process.

main advantageS

CTTS is an innovative technology aimed at simplifying the cell shipping process and providing a practical, cost-efficient and time saving solution to the complex cell logistics. Some of the technology’s main advantages are:

• Universal cell and tissue shipping system: CTTS has proven to be a highly efficient shipping technology for a wide range of cells of different profile (e.g. SK-N-MC, MDCK-II and MDCK-II-MDR1, CHO, cells of murine origin, mesenchymal cells, keratinocytes, fibroblasts, etc…). Cells can be shipped attached or in suspension, in various plate formats, flasks, tubes...

• Optimal cell viability results after shipment in CTTS media at room temperature, for an extended shipping time frame of four days to one week.

• Easy-to-use: CTTS shipping media is extremely easy to prepare and remove at destination, not requiring lengthy culture recovery techniques and thus drastically saving time and efforts.

• Ready-to-use: Cells can be shipped in the same format on which the assays are going to be carried out. Since cells are not frozen, CTTS medium can be easily removed directly upon arrival, leaving the cells ready to be used in a wide range of studies (e.g. functional test, morphological studies, gen & protein expression studies, cell proliferation, apoptosis, differentiation and response, biomarker expression, etc…).

• Cost efficient: Cells in a CTTS based, ready-to-use format are delivered fresh in small, single use, insulated boxes.

Technology Offers · HealTH 63

Page 64: Biotechnology Basque Country

applicability of the technology

CTTS Technology™ is mainly intended for the development of ready-to-use cell based assay models for research use. Ideally, this technology is of relevance to companies involved in the development and commercialisation of such models for research activities, as well as for specialized cell culture media manufacturers interested in the commercialisation of the CTTS shipping media for complementary purposes.

current Stage of development

The CTTS Technology™’s development has been completed and protocols are now available for the preparation of the shipping medium, the arrangement of the cells prior to the shipment and for the recovery of the culture at destination.

exploitation of rtd reSultS

Histocell’s CTTS Technology™ has been fully developed in-house, by the initiative of Histocell, SL, which holds full rights over the technology.

intellectual property rightS

The International patent request was filed at the European (as an International PCT file) Patents Offices to register Histocell CTTS Technology™ and obtain industrial property rights over this invention.

*European Patent Office – International Application No. : PCT/EP2009/009132:

This international patent has been already granted in uSA, Europe and Canada. The patent has been also filed in Japan.

collaboration type

Histocell’s aim is to out-license the CTTS Technology™ to companies involved in the development and commercialization of ready-to-use cell based assay models, cell lines and tissue for research applications. In line with this strategy, Histocell is open to negotiating the transfer of the CTTS Technology™ to interested parties holding a firm position in the above mentioned business fields and underlines its commitment to collaborate, should it be necessary, in any product adaptability procedure which may add value to the technology in question and facilitate a licensing operation. Histocell is also open to evaluating potential collaboration opportunities on the basis of a joint research agreement for the development and commercialisation of innovative, high added value combination products which may contribute to strengthening the market penetration of the CTTS Technology.

64 Technology Offers · HealTH

Page 65: Biotechnology Basque Country

Technology Offers · HealTH 65

Page 66: Biotechnology Basque Country

abStract of technology to exploit

Organic and inorganic dispersions for diagnostic reagents (turbidimetry, slide agglutination, immunocromatography, quimioluminiscence), protein purification systems, calibration standards, colloidal models, photonic crystals …

deScription

The commitment of IKERLAT Polymers is to offer the best support to the companies in the different fields they are working for. We take pride in not only our dispersions, but also in our personalized technical service giving to the customer a satisfactory selection of beads for each application.

We offer the possibility of developing the customer required product, adjusting characteristics as the particle size, particle surface chemistry and density, colour and/or fluorescent properties and/or magnetic properties of the dispersion and the volume of the lot. The aim of IKERLAT Polymers is to drive to our customers to the exact product they need.

innovative aSpectS

Our capacity of developing the customer required product, adjusting characteristics as the particle size, particle surface chemistry and density, colour and/or fluorescent properties and/or magnetic properties of the dispersion, the volume of the lot …

The aim of IKERLAT Polymers is to drive to our customers to the exact product they need, supporting the costs related to the R & D and manufacture of the first small quantities required for their manufacturing and R&D processes.

promoter organization identification

organization name IKERLAT Polymers, S.L.

contact Joxe Sarobe

email [email protected] www.ikerlatpolymers.es

phone +34 943 16 47 24

fax +34 943 88 07 27

description of the organization

IKERLAT Polymers is a specialized company in the microspheres world. The wide experience of IKERLAT staff in the field of emulsion polymerisation allows us to offer a complete range of services including good polymer beads (plain polystyrene and functionalised polymer dispersions, dyed beads, fluorescent particles, magnetic beads …) and excellent technical service.

activity Chemistry

markets tackled Diagnostic reagents, biological/biotechnological fields, protein purification systems, calibration standards, colloidal models, photonic crystals.

Size -

Organic and inorganic dispersions for diagnostic reagents and biological/biotechnological fields

66 Technology Offers · HealTH

Page 67: Biotechnology Basque Country

main advantageS

• Personalized R&D and manufacture of the products.

• Characterization service of their dispersions.

• Fine reproducibility lot-to-lot.

applicability of the technology

Diagnostic reagents, biological/biotechnological fields, protein purification systems, calibration standards, colloidal models, photonic crystals …

current Stage of development

Complete stage.

exploitation of rtd reSultS

All the products we develop, manufacture and commercialise are manufactured in IKERLAT Polymers.

collaboration type

Personalized: Customer-IKERLAT Polymers.

Consortium: enterprises, Technological Centres and/or universities.

kind of agreement Sought

Development, manufacture and supply of different dispersions. R&D, personalized or in consortium, of new products and reagents.

Technology Offers · HealTH 67

Page 68: Biotechnology Basque Country

abStract of technology to exploit

Derivation of human induced Pluripotent Stem Cells (iPSC-s) from healthy donors and donors with different pathologies, using integrative and non-integrative approaches.

deScription

Inbiomed is a private research foundation dedicated to biomedical research and regenerative medicine. Besides the research laboratories, Inbiomed has 4 Core Facilities to aid research, providing vital support to the work done by investigators. One of these Core Facilities is the Cell Reprogramming and Differentiation Core Facility that aims to facilitate and to optimize the derivation of human induced Pluripotent Stem Cells (iPSC-s). The Core Facility offers several services divided by modules:

• Module 1: fibroblasts isolation from skin biopsy.

• Module 2: fibroblasts reprogramming using integrative or non-integrative methods.

• Module 3: basic characterization: pluripotency and in vitro differentiation markers.

• Module 4: teratoma formation.

• Module 5: karyotyping.

• Module 6: DNA fingerprinting.

Inbiomed owns a biobank called Inbiobank that aims to isolate and store adult primary stem cells with high quality standards from different human tissues for use by researchers at the national and international level. The traceability of the production process is certified by ISO9001. Inbiobank is a node of the Banco Nacional de Líneas Celulares, so iPSC-s will be generated under Spanish legislation (BNCL-ISCIII).

For more information, please check Inbiomed´s website www.inbiomed.org

promoter organization identification

organization name Inbiomed

contact Naiara Tejados

email [email protected]

phone +34 943309064

fax +94 943308222

description of the organization

Private foundation

activity Biomedical research and regenerative medicine

markets tackled Pharmaceutical, biotechnological

Size 27 employees

Derivation of human induced Pluripotent Stem Cells (iPSC-s)

68 Technology Offers · HealTH

Page 69: Biotechnology Basque Country

innovative aSpectS

The Cell Reprogramming and Differentiation Core Facility offers the external researchers the possibility to derive induced Pluripotent Stem Cells, and fully characterize them with all the required analyses to make sure they have been correctly reprogrammed.

main advantageS

The Cell Reprogramming and Differentiation Core Facility is a technical unit supported by a center specialized in Regenerative Medicine and conducted by researchers with rigorous and specific scientific criteria and experience.

Fibroblast isolation and expansion from the original tissue sample can be performed in the institute as well, and the researcher can also have Access to the several fibroblast lines deposited in Inbiobank to be used as the starting material.

applicability of the technology

Stem cell research, advanced therapies, regenerative medicine.

current Stage of development

The Cell Reprogramming and Differentiation Core Facility has been reprogramming cells since 2012.

collaboration type

Contracts with researchers or clinical trial promoters are sought.

Technology Offers · HealTH 69

Page 70: Biotechnology Basque Country

abStract of technology to exploit

GMP standards in viral vector production and flow cytometry.

deScription

Inbiomed is a private research foundation dedicated to biomedical research and regenerative medicine.

Besides the research laboratories, Inbiomed has 4 core facilities to aid research, providing vital support to the work done by internal and external researchers, placing the best trained staff at their disposal as well as cutting-edge equipment and technology in regenerative medicine:

1. Cell Reprogramming and Differentiation Platform.

2. Cytometry and Advanced Optical Microscopy Platform.

3. Viral Vector Platform.

4. Animal Model Platform.

All the facilities have long been running and offering services to external researchers. All the protocols are now set up and both the Viral Vector Platform and the Cytometry and Advanced Optical Microscopy Platform comply with the requirements of the Standard UNE-EN ISO 9001:2008.

Due to the increasing needs, both the Viral Vector Platform and the cytometry and advanced optical microscopy Platform are now working to get the GMP certification.

Any customers needing viruses for gene therapy trials, or willing any cells to be characterized by flow cytometry for clinical applications may contact the person above and request updates.

promoter organization identification

organization name Inbiomed

contact Naiara Tejados

email [email protected]

phone +34 943309064

fax +94 943308222

description of the organization

Private foundation

activity Biomedical research and regenerative medicine

markets tackled Pharmaceutical, biotechnological

Size 27 employees

GMP standards in viral vector production and flow cytometry

70 Technology Offers · HealTH

Page 71: Biotechnology Basque Country

innovative aSpectS

The viral vector production, and the analytical flow cytometry, the cell sorting and the advanced optical microscopy services of Inbiomed comply with the requirements of the Standard UNE-EN ISO 9001:2008.

Inbiomed aims for getting the GMP certification in the following processes:

• Viral vector production for gene therapy.

• Analytical flow cytometry for cell therapy.

main advantageS

GMP certification for clinical-quality viruses for gene therapy and to cell characterization by cytometry to be used in cells therapy

applicability of the technology

Gene therapy, cell therapy, advanced therapy medicinal products.

current Stage of development

The viral vector production (planned for 2015) and the analytical flow cytometry (planned for 2014) are now working on and aim for getting the GMP certification.

collaboration type

Contracts with researchers or clinical trial promoters are sought.

Technology Offers · HealTH 71

Page 72: Biotechnology Basque Country

abStract of technology to exploit

Our research areas are:

• Electrochemical and optical biosensors.

• Micro/nanotexturing for cell differentiation and proliferation.

deScription

• Chronoamperometric sensors.

• Optical sensors based in localised surface plasmon resonance.

• Ultra-short pulse laser 2D and 3D micro/nanostructuring.

• Surface nanoestructuring by nanoimprint lithogtraphy.

innovative aSpectS

The technologies applied by IK4-TEKNIKER are selected by its potential to be scaled-up to obtain low unit costs when mass manufactured. The industrialization of the technologies validated at lab level are implemented at low risk.

main advantageS

For sensors and depending on the application, two main advantages could be obtained, increase of sensitivity comparing to conventional technologies and multiplexing.

For micro/nanostructuring we can apply the texturing to a braod range of materials y also for some of them 3D structuring is possible.

promoter organization identification

organization name Fundación IK4-TEKNIKER

contact Sabino Azcárate

email [email protected]

phone +34607180533

fax + 34943202757

description of the organization

IK4-TEKNIKER is a technological centre and legally constituted as a private not-for-profit Foundation. Its mission is to help the industrial sector to increase its innovative capacity by means of generating and applying technology and knowledge in order to be more competitive.

activity CRO for biomarker detection technologies and surface texturing for tissue engineering.

markets tackled Biomedical and Pharmaceutical

Size 265

Biosensors and micro/nanostructuring technologies

72 Technology Offers · HealTH

Page 73: Biotechnology Basque Country

applicability of the technology

Companies looking for improved in-vitro diagnostics devices are potential customers of our sensors technologies.

The productivity of manufacturing based processes for cell therapies could be improved by using micro/nanostructured substrates.

current Stage of development

Most of developments are validated at lab scale and ready to be scaled-up in order to be exploited. Some degree of customization will be required.

intellectual property rightS

Some specific application of texturing of substrates for tissue engineering are protected by IPR.

collaboration type

IK4-TEKNIKER has a large experience in leading and collaborating in the frame of projects supported by regional, national and Eu-ropean funds. Also we have a well established reputation as CRO with the most important biotech companies in Spain.

We are looking for biotech companies interested in developing new products based on our sensor and structuring technologies. Also research organisations (universities, Institutes, ..) with in-terest in long-term projects.

Technology Offers · HealTH 73

Page 74: Biotechnology Basque Country

abStract of technology to exploit

The mechanism of action assessment of a drug requires the quantification of a biological response that may involve cell biological actions as proliferation or cell death, cell metabolism or intracellular signalling. These biological mechanisms can be measured by receptor activation, receptor binding or gene reporter using cell-based assays.

deScription

Innoprot Assay Development Platform is focused on functional assays due to their important role to move from in-vitro to in-vivo pharmacology for a high range of drug targets. It can be directed toward the best detection technology for a given molecular target and screening objective.

Functional & Expression Assays for a wide variety of genes including:

• GPCRs

• Ion channels

• Proteases

• kinases as well as various other enzymes

• Transmembrane proteins

• Adhesion molecules.

Depending on the specific characteristics of each target, the assays can be developed in different formats:

• Fluorescent-based cellular Assays (tGFP)

• Cell viability Assays (MTS)

• Calcium dyes & Voltage-sensitive dyes

• Labelling chemistry

• Reporter Gene Assays

promoter organization identification

organization name Innoprot

contact Jorge Gámiz

email [email protected]

phone +34 944005355

fax +34 946579925

description of the organization

Innoprot is a dynamic and R&D intensive biotech focused on developing cell-based assays for High-Throughput Screening and High-Content Analysis. Innoprot also acts as a CRO providing drug screening services and on-demand assay development. Our goal is to accelerate and improve our customer’s drug discovery programs.

activity Cell-based assays, Drug Screening, HTS, HCS

markets tackled Pharmaceutical & Biotechnology companies, Research Centers, Government Institutions

Size 12

Cell-based Assay Development

74 Technology Offers · HealTH

Page 75: Biotechnology Basque Country

innovative aSpectS

Innoprot uses a novel fluorescent technology licensed by EVROGEN to develop cell-based assays. Destabilized fluorescent variant allows accurate analysis of rapid and/or transient events in gene regulation.

main advantageS

Innoprot cell-based assays are well-suited to measure GPCRs activation. Due to their high sensibility and accurately, they are also ideal for any other cellular targets, like ion channels, kinases, adhesion molecules or transmembrane proteins. All of our assays are HTS compatible and can be used in primary or secondary screening.

applicability of the technology

• Fluorescent-based cellular Assays (tGFP)

• Cell viability Assays (MTS)

• Calcium dyes & Voltage-sensitive dyes

• Labelling chemistry

• Reporter Gene Assays

current Stage of development

The Assay Development Platform offered by Innoprot is being commercialized

collaboration type

Distribution, Commercial Agent or Acquisitions.

Technology Offers · HealTH 75

Page 76: Biotechnology Basque Country

abStract of technology to exploit

Recombinant MDCK cells stably expressing human amiloid precursor protein (APP) fused to the C-terminus of enhanced turbo green fluorescent protein (tGFP). The Secretase Activity Assay is designed to assay for compounds inducing APP vesicularization by monitoring the translocation of a tGFP-C terminal APP fusion protein from the cytoplasm to vesicles.

deScription

A novel MDCK/tGFP-APP cell line has been developed through stable transfection for monitoring the activity of the secretases in cell-based assays. MDCK/tGFP-APP cell line was obtained by transfection of an expression vector for a fusion protein of turboGFP and human deletion mutant APP in the Cterminal, as well as G418 into MDCK cells with Evrogen TurboGFP. Cells were then grown in the presence G418. Single cells with strong green fluorescence were selected by flow cytometry, and allowed to expand. These cells constitutively express the APP-tGFP fusion protein.

Recombinant MDCK cells stably expressing human amiloid precursor protein (APP) fused to the C-terminus of enhanced turbo green fluorescent protein (tGFP). The Secretase Inhibitor Assay is designed to assay for compounds inducing APP vesicularization by monitoring the translocation of a tGFP-C terminal APP fusion protein from the cytoplasm to vesicles. APP vesicularization can be promoted by the DAPT (γ-secretase) and ß-secretase inhibitor II which are used as reference compound in this assay.

APP vesicularization can be imaged on most HCS platforms and fluorescence microscopes.

promoter organization identification

organization name Innoprot

contact Jorge Gámiz

email [email protected]

phone +34 944005355

fax +34 946579925

description of the organization

Innoprot is a dynamic and R&D intensive biotech focused on developing cell-based assays for High-Throughput Screening and High-Content Analysis. Innoprot also acts as a CRO providing drug screening services and on-demand assay development. Our goal is to accelerate and improve our customer’s drug discovery programs.

activity Cell-based assays, Drug Screening, HTS, HCS

markets tackled Pharmaceutical & Biotechnology companies, Research Centers, Government Institutions

Size 12

Recombinant stable cell line for secretase activity assessment of potential drugs for Alzheimer’s disease

76 Technology Offers · HealTH

Page 77: Biotechnology Basque Country

innovative aSpectS

MDCK/tGFP-APP stable cell line developed by Innoprot is the only one in the market that allows screen potential ß-secretase & γ-secretase inhibitors by fluorescence images on High-Content Screening Platforms and fluorescent microscopes by tGFP-APP vesicularization.

main advantageS

• Designed to assay compounds for their ability to inhibit ß-secretase & γ-secretase activity.

• Coupled to tGFP for easy monitoring of the cellular vesicularization event

• Robust cell-based assay for use in high content analysis and fluorescence microscope application

applicability of the technology

Drug Discovery & Development in Alzheimer Disease - Designed to assay compounds for their ability to inhibit ß-secretase & γ-secretase activity.

current Stage of development

MDCK/tGFP-APP stable cell line offered by Innoprot has been tested and it is being commercialized.

collaboration type

Distribution, Commercial Agent or Acquisitions.

Technology Offers · HealTH 77

Page 78: Biotechnology Basque Country

abStract of technology to exploit

Nomad Technology consists in a family of fluorescent biosensors which allow the measurement of second messengers (cAMP, Ca++, DAG) concentration changes in living cells by fluorescent imaging analysis on most HCS platforms.

deScription

Innoprot has developed a novel family of biosensors for measuring GPCR activity in living cells using the same fluorescent backbone. Each biosensor of the family co-expressed with a GPCR, provides an innovative and sensitive research tool for studying the molecular mechanism and kinetics of GPCR activation. NomadTM biosensors enable the measurement of second messenger concentration changes involved in GPCR activation. An increase in the second messenger concentration leads to a change in the structural folding of NomadTM biosensor that promotes its cellular relocation. The molecular structure of Nomad biosensors comprises: a membrane localization peptide, a second messenger transduction protein binding peptide, a reticulum retention signal and a fluorescent peptide. Based in these components, the second messenger transduction protein binding peptide could be replaced depending on the second messenger involved in the GPCR activation pathway, resulting three different versions of NomadTM biosensors: cAMP, Ca++ and DAG.

innovative aSpectS

This new technology allows perform screening campaigns measuring second messenger concentration changes in living

promoter organization identification

organization name Innoprot

contact Jorge Gámiz

email [email protected]

phone +34 944005355

fax +34 946579925

description of the organization

Innoprot is a dynamic and R&D intensive biotech focused on developing cell-based assays for High-Throughput Screening and High-Content Analysis. Innoprot also acts as a CRO providing drug screening services and on-demand assay development. Our goal is to accelerate and improve our customer’s drug discovery programs.

activity Cell-based assays, Drug Screening, HTS, HCS

markets tackled Pharmaceutical & Biotechnology companies, Research Centers, Government Institutions

Size 12

NomadTM Technology: The New Generation of Biosensors for HCS

78 Technology Offers · HealTH

Page 79: Biotechnology Basque Country

cells by fluorescence imaging. It could be applied to GPCRs activation/inhibition studies, primary cells or to orphan receptors because this technology allows perform multiplex assays.

main advantageS

• Allow perform multiplex analysis

• Different second messenger application: cAMP. Ca++, DAG

• Assays are performing in living cells

• High sensitivity in robust assays

• Non-tagged GPCRs

• Economic assay. It is not required to use additional reagents to perform the determinations.

applicability of the technology

• High Content Screening for GPCR activity in living cells

• Live cell imaging to follow cellular effect kinetics of GPCR activation

• High Throughput Screening based in fluorescent imaging

• cAMP & Ca++ concentration changes determination in primary cells

• Orphan GPCRs

• Phenopytic Screening

current Stage of development

• Technologoy has been already validated and it is being commercialized.

intellectual property rightS

PCT accepted. Patent Pending

collaboration type

Licensing, distribution, commercial agreement

Technology Offers · HealTH 79

Page 80: Biotechnology Basque Country

abStract of technology to exploit

Labsan offers specialised research and development services within the pharmaceutical, biotechnological, cosmetic and medical devices sectors. Those services are summarized as follows:

• Galenical development.

• Analytical development and validation.

• Pharmaceutical process design, optimization and validation .

• Scaling-up services: Our laboratory is specially equipped to offer GMP scaling-up services within a wide range of dosage forms.

• Pharmaceutical product manufacturing: Innovative Medicinal Products, pilot batches, stability batches, semiindustrial batches.

• Medical devices manufacturing.

• Medication for clinical trials: Medication masking and placebo manufacturing. Randomization plans and specific labelling.

• Quality control and drug product release.

• Assessment on Quality Assurance.

Our manufacturing facilities comply with Good Manufacturing Certificate (cGMP) for both industrial and Innovative Medicinal Products and ISO 13485 for Medical Devices.

The laboratory has specific equipment to manufacture the following dosage forms:

• Solid forms: Tablets and capsules.

• Semi-solids forms: Creams, ointments, emulsions and gels.

• Liquid forms: Syrups, drops and oral solutions.

promoter organization identification

organization name Laboratorium Sanitatis, S.L. Tecnalia (LABSAN)

contact Itziar Echevarría

email [email protected]

phone +34 902 760 000

fax +34 945 298217

description of the organization

Pharmaceutical Laboratory

activity Research and development of pharmaceutical products and services

markets tackled Pharma, Cosmetics, Clinics, Biotech, Medical Devices

Size SME

Pharmaceutical development, scale-up and manufacturing of medicinal products and investigational medicinal products for clinical trials

80 Technology Offers · HealTH

Page 81: Biotechnology Basque Country

Our laboratory also includes sterile manufacturing facilities with class A and class B capability for product development.

Equipment available in classified areas: Granulator/intensive mixer, fluid-bed dryer and static dryer, tableting machine, control system equipment and metal detector, capsule filling machine, drum for film-coating systems, weighting systems, automatic blister machine, semisolid and liquid filling, capping and labelling machine, reactors, stirrers and mixing tanks.

Available equipment in quality control laboratory: High Performance Liquid chromatographer (HPLC – UV diode array detector), infra-red spectrometer, uV spectrophotometer, TOC (Total Organic Carbon) analyser, Karl-Fischer titrate, dissolution tester, durometer, friability tester, disaggregation tester, viscosimeter.

deScription

Created as a spin-off of Leia Technological Centre now integrated within Tecnalia, Labsan offers specialized research and development services within the pharmaceutical, biotechnological and cosmetic sectors of national and international markets.

The aim of our company is to contribute to human health by promoting innovative research lines focused on new pharmaceutical products.

The main goal of Labsan is to provide pharmaceutical services and products under the most severe GMP/GLP quality standards.

Labsan is an authorized pharmaceutical laboratory since 2005 and complies with Good Manufacturing Certificate (cGMP) for both industrial and Innovative Medicinal Products and ISO 13485 for Medical devices.

Labsan facilities are located in the Technological Park of Alava within a 1470 m2 ground area. The laboratory has specific equipment to manufacture a broad range of dosage forms.

innovative aSpectS

Labsan created to manufacture pilot batches and clinical batches of pharmaceutical products is authorised in a wide range of pharmaceutical dosage forms.

Labsan provides a full range of services including: drug formulation, development and validation of analytical methods, quality control and batch release, scale-up, GMP manufacturing and clinical trial logistics management.

main advantageS

The main goal of our company is to provide pharmaceutical services and products under the most severe GMP/GLP and ISO 13485 quality standards.

A team of highly qualified professionals with an important background in pharmaceutical industry offers advice, experimental design and state-of-the-art protocols.

We offer personalized development solutions and complete project services.

applicability of the technology

• Pharmaceutical sector group.

• Cosmetic sector group.

• Biotechnology sector group.

• Clinical-sanitary sector group.

• Medical Devices sector group

current Stage of development

Currently prototypes, pilot batches and industrial batches for the authorized pharmaceutical dosages have been manufactured.

Technology Offers · HealTH 81

Page 82: Biotechnology Basque Country

intellectual property rightS

Property right conditions are specifically agreed for each project.

collaboration type

Currently Labsan collaborates with the scientific teams of several research units (technological centres, universities, pharmaceuti-cal companies or clinical research centres). Collaborations are al-ways made under confidential private contracts.

Our cooperation is offered to customers who require high quality pharmaceutical products or services.

82 Technology Offers · HealTH

Page 83: Biotechnology Basque Country

Technology Offers · HealTH 83

Page 84: Biotechnology Basque Country

abStract of technology to exploit

Lipid nanoparticles (LNs) made with a solid matrix are derived from oil-in-water nanoemulsions formed by replacing liquid oil with a solid lipid. Their mean particle size is between 50 and 1000 nm.

LNs have been developed as potential alternatives to other conventional drug delivery systems such as polymeric nanoparticles, liposomes, and emulsions.

LNs are well-tolerated and efficient carrier systems for parenteral, oral, inhalational, ocular and dermal applications.

Labsan has specific know how and equipment to develop the following activities:

• Research on new delivery systems: Lipid Nanoparticles, Microparticles, and Microemulsions.

• Scale-up services for lipid nanoparticles: GMP scaling-up services within a wide range of final dosage forms:

· Solid forms: Tablets and capsules.

· Semi-solids forms: Creams, ointments, emulsions and gels.

· Liquid forms: Syrups, drops and oral solutions.

• Analytical development and validation.

Equipment available in classified areas: High Pressure homogenization equipment, granulator/intensive mixer, fluid-bed dryer and static dryer, tableting machine, control system equipment and metal detector, capsule filling machine, drum for film-coating systems, weighting systems, automatic blister machine, semisolid and liquid filling, capping and labelling machine, reactors, stirrers and mixing tanks.

Available equipment in R&D and quality control laboratory: High Performance Liquid chromatographer (HPLC – UV diode array detector), infra-red spectrometer, UV spectrophotometer, TOC (Total Organic Carbon) analyzer, Karl-Fischer titrator, dissolution tester, durometer, friability tester, disaggregation tester, viscosimeter.

promoter organization identification

organization name Laboratorium Sanitatis, S.L. Tecnalia (LABSAN)

contact Itziar Echevarría

email [email protected]

phone +34 902 760 000

fax +34 945 298217

description of the organization

Pharmaceutical Laboratory

activity Research and development of pharmaceutical products and services

markets tackled Pharma, Cosmetics, Clinics, Biotech, Medical Devices

Size SME

Development and manufacturing of lipid nanoparticles as drug delivery systems

84 Technology Offers · HealTH

Page 85: Biotechnology Basque Country

deScription

Labsan has been working for several years in hot homogenization technology for the manufacture of lipid nanoparticles, being this technology the only one valid for scale-up processes and validated under GMPs

Labsan produces pilot batches under GMP standards with sizes up to 5 -10 kg.

innovative aSpectS

Although initially it was created to manufacture pilot batches and clinical batches of pharmaceutical products, Labsan has strongly focused on R&D innovative lines.

The first R&D aim of our company is to investigate and develop new drug carrying systems. Labsan addresses several projects were new drug delivery technologies are involved.

Technological innovation during the last years around nanotechnology allows the research of a more efficient method of delivering medications to specific tissues. Currently Labsan is involved in the optimization and development of solid lipid nanoparticle systems for dermic and oral formulations.

main advantageS

Advantages of lipid nanoparticles:

• Small size and relatively narrow size distribution permits specific drug delivery.

• Controlled and sustained release of active drugs can be achieved.

• Improved bioavailability

• Controlled release by incorporation of poorly water soluble drugs in the solid lipid matrix.

• Easy to scale up.

• Chemical protection of labile compounds.

• No special solvent required.

• Conventional emulsion manufacturing methods applicable.

• High long-term stability results.

• Versatile applications

applicability of the technology

• Pharmaceutical sector group.

• Cosmetic sector group.

• Biotechnology sector group.

• Clinical-sanitary sector group.

• Medical Devices sector group

current Stage of development

Currently prototypes and pilot batches have been manufactured of topical and oral formulations containing lipid nanoparticles.

exploitation of rtd reSultS

The development of topical and oral pharmaceutical formulations containing lipid nanoparticles is the result of a research carried out in collaboration with Tecnalia Research and Innovation. The area of Health and Quality Life of Tecnalia has worked since its beginnings in various projects for the development of new drug delivery systems.

collaboration type

Currently Labsan collaborates with the scientific teams of several research units (technological centres, universities, pharmaceutical companies or clinical research centres). Collaborations are always made under confidential private contracts.

Our cooperation is offered to customers who require high quality pharmaceutical products or services.

Technology Offers · HealTH 85

Page 86: Biotechnology Basque Country

abStract of technology to exploit

Our product line consists of a series of PVD coatings which are known for their extreme hardness, low chemical reactivity, high oxidation and wear resistance.

These properties make our coatings suitable for applications were a cutting process is involved, specifically for improving the lifetime of cutting tools used to cut metals such as steels, titanium, aluminium, heat resistant alloys and other materials such as graphite, carbon fibre based composites, wood and human bones.

Our technology is provided by a well known PVD unit manufacturer: PLATIT. Their technology is currently applied worldwide in the markets mentioned above. As an example, they are a main provider of the Swiss PVD biotechnology market and currently coat titanium and stainless steel implants and cutting tools for surgery and dental fields.

deScription

Our products are ceramics made of metal nitrides or carbonitrides produced by Physical Vapour Deposition in PLATIT high vacuum units.

Our coating portfolio includes TiN, TiCN, CrN, TiCrN, ZrN, TiAlN, AlTiN, TiAlCN, DLC-s, AlCrN, AlCrSiN, AlTiSiN, etc.

The hardness values of these coatings are between 1800 HV0.05 and 4500 HV0.05.

The oxidation resistance of our coatings covers the range between 400 ºC and 1200 ºC.

The substrates we coat include alloyed steels, hardmetals, ceramics, titanium and other metals. We also offer a decoating service of our products, when needed.

promoter organization identification

organization name METAL ESTALKI, S.L.

contact Ibon Azkona

email [email protected]

phone +34 944 544 798

fax +34 944 544 805

description of the organization

Our Company offers a coating service of hard PVD ceramic coatings to manufacturers, end users and traders of tools and parts which value is increased by applying a PVD coating. Our technology is provided by the Swiss company PLATIT.

activity PVD coating service

markets tackled Aeronautics, automotive, food industry, machine tool industry, biotechnology, etc.

Size 18 employees

PVD ceramic coating for biotechnology and medical applications

86 Technology Offers · HealTH

Page 87: Biotechnology Basque Country

innovative aSpectS

Our company is the only Spanish provider of ultrahard nanocomposite coatings developed by Platit, as long as tailored coatings for biomedical applications.

main advantageS

Among the most successful applications we could remark the use of nanocomposite PVD coatings for coating tools which work machining titanium and Inconel, grafite and CFC based materials. We also offer some dedicated coatings to be applied on implants designed by Platit.

collaboration type

We offer a fast coating service within Spanish market to custom-ers who need a PVD coating on their products the use or sell. Our service would be useful for foreign manufacturers who are interested in Spanish market and needs to offer quality coated products but needs to avoid a stock of coated products.

Our cooperation is offered to customers who import high quality PVD coated products and who would need a better PVD coating than their standard, a service to recoat or alternatively a service to regrind, de-coating and recoating.

Technology Offers · HealTH 87

Page 88: Biotechnology Basque Country

abStract of technology to exploit

ONDAX Scientific is an independent Contract Research Organization (CRO) specialized in providing high quality Animal Health Clinical Trial and Development services to the Pharmaceutical and Biotechnology industry.

We offer a full range of clinical development services for Clinical Trials in the Animal Health field. Main activities include Clinical Trial Monitoring, Co-ordination, Data Management, Biostatistics, Quality Assurance and Regulatory Affairs.

deScription

The main services that we offer include coordination and management of all clinical trial activities. These include Protocol Development, Case Record Form design (CRF), Electronic Data Capture (EDC) related activities, Regulatory Test Permit Approvals, Study Site and Investigator selection, Clinical Trial Monitoring, Final Study Report Development & Publications

Additional activities included:

• Data Management of the Clinical Trial data which includes database design, electronic Case Record Form design, entry, coding, query resolution and export activities using our ORACLE based in-house software which is compliant with regulatory requirements including FDA “Guidance For Industry: Computerized systems used in clinical investigators and 21 CFR Part 11 document.

• Biostatistics - Statistical analyses of Clinical Trial data, interpretation and preparations of Study Reports.

• Quality Assurance of all aspects of the Clinical Trails process including Protocol and case Records Form audits, Investigator & Study Sites audits, Clinical Trial documentation audits, Data & Database Management

promoter organization identification

organization name ONDAX Scientific S.L.

contact Patxi Sarasola

email [email protected]

phone +34 943 646087

fax +34 943 64 6158

description of the organization

Independent Contract Research Organisation (CRO)

activity Provision of clinical development services to the Pharmaceutical Industry

markets tackled Animal Health Pharmaceutical and Biotechnology companies.

Size SME

Clinical Trials in Animal Health

88 Technology Offers · HealTH

Page 89: Biotechnology Basque Country

audits. In addition the following services can also be contracted:

· Training in VICH-GCP.

· Design & development of Standard Operating Procedures (SOPs).

· Development & setting up quality systems at external sites.

· Consultancy services.

• Regulatory Affairs – including Pre-Clinical & Clinical Expert reports, Test Permit Applications, Regulatory Filings.

innovative aSpectS

There are many reasons for choosing ONDAX Scientific, some of which include:

• A multidisciplinary, multilingual scientific team highly experienced in Veterinary Clinical Trials and regarded as one of the top three European specialists in this area.

• A company structure that allows us to be totally flexible and highly responsive to individual client requirements.

• A working philosophy based on client focus, high quality standards and operating within agreed timelines.

• We are totally committed to our projects: what’s good for our clients is good for us.

• We commit to providing a professional, dedicated and high quality service to all our clients.

main advantageS

We have offices based in Hondarribia, on the French/Spanish border close to several airports, and in Horsham, England a short distance from London Gatwick Airport. Our close proximity to excellent travel connections allows our staff to travel easily within the uK and most of central Europe.

applicability of the technology

Our specialised team of international and multilingual staff comprise of scientists, veterinarians and pharmacists. Our expertise includes:

• VICH-GCP Clinical Trials.

• Prescription Diet Trials.

• Post-registration Trials .

• Palatability Trials.

• Epidemiological studies.

• Market surveys for new products/claims.

• Pilot Clinical Trials (Go/No Go Decision).

current Stage of development

Since our creation in the year 2000, our portfolio of business clients has rapidly increased and today we collaborate with numerous companies in the pharmaceutical sector. Our clients range from large multinationals to small biotechnology companies with most of our clients choosing us as their veterinary Clinical Trial partners time and time again. This consistent high level of client satisfaction has made us one of the leading European specialists in Clinical Trials.

collaboration type

Interested in collaborations with any company wishing to develop their products for the animal health market (both companion animals and livestock). These include Animal Health Pharmaceutical companies, other Contract Research Organisations and Biotechnology companies.

Technology Offers · HealTH 89

Page 90: Biotechnology Basque Country

abStract of technology to exploit

Metabolomics:

A combination of data-rich analytical chemistry and chemometrics for profiling metabolism in complex systems.

Metabolomics involves the extraction and measurement of multiple small molecules from tissues or biofluids to produce metabolic profiles. Comparison of such profiles from different phenotypes can be used to identify specific metabolic changes leading to the understanding of physiology, toxicology and disease progression. The less complex, more quantitative, biochemically specific metabolomics approach is proving advantageous over rival technologies such as genomics, transcriptomics and proteomics and is growing rapidly in an increasing range of fields such as disease diagnosis, drug development, plant science, and nutrition.

deScription

OWL has established a state-of-the-art mass spectrometry based metabolomics platform ideally suited for the study of liver disease biomarkers, currently the company’s main research front. In addition to this ongoing research effort, OWL conducts metabolomics studies for other pharmaceutical and biotechnology companies in key areas such as biomarker discovery, clinical studies, diagnostics and toxicology.

Metabolomics is the study of small organic molecules, named metabolites, present in a given biological system. This emerging research field of “omics” sciences can provide a general view of metabolomics state and of biochemical interaction connected to a studied system biology. Besides, metabolomics reflects phenotype, revealing system biology response to genetics, nutritional and environmental influence.

promoter organization identification

organization name OWL Metabolomics (One Way Liver Genomics S.L)

contact Teresa Porto

email [email protected]

phone 00 94 4318540

fax 00 94 4317140

description of the organization

OWL is a biotechnology company in the field of Metabolomics with pioneering diagnostics products and unique R&D services for the scientific community, biotech and pharmaceutical companies

activity Metabolomics, diagnostics, biomarker discovery, companion diagnostics, CRO

markets tackled Biotech and pharmaceutical companies, Research Centers, Food and Cosmetics companies

Size SME

Metabolomics and Lipidomics products and services provider

90 Technology Offers · HealTH

Page 91: Biotechnology Basque Country

Some of the most outstanding aspects of metabolomics applications include:

• Screening Services: metabolomics global approach allows sample classification and provides with a comprehensive perspective to explore the numerous factors that govern a system biology.

• Biomarker search/identification: search for a metabolite indicative of normal biological process, pathological process or a response to a therapeutic or nutritional intervention. Among them there are diagnostic markers (allow for disease classification), prognostic markers (enable disease emergence/ development) and predictive markers (revealing response to a certain treatment)

• Companion diagnostics: studies focused on helping the clinicians in making treatment decisions for their patients.

• Drug development optimization: New drug effect evaluation during early stages development, in endogenous or xenobiotic metabolism, focusing on human efficacy/toxicity prediction.

Mass spectrometry (MS) based metabolomics offers selective, sensitive analyses with the potential to identify metabolites. The analytical platform at OWL includes several liquid-chromatog-raphy interfaced mass spectrometers ideally suited to metabo-lomics applications.

innovative aSpectS

OWL has developed a comprehensive set of Metabolomics tools, which makes possible the discovery and identifica-tion of biomarkers for either research or diagnostics purposes. It is a state of the art technology that combines ultra performance liquid chromatography with mass spectrometry (UPLC-MS), and that allows OWL to offer a novel metabolomics service, with po-tential clients in hospitals, research centers, and biotechnology and pharmaceutical industries.

Thus, OWL has established a leading position in personalized medicine for liver disease, specifically, non-alcoholic steatohepa-titis (NASH) and is currently introducing the first in vitro serum based diagnostic for NAFLD and NASH, based on the studies on hepatic diseases carried out by Dr. Mato.

The current clinical diagnosis for NASH is based on liver biopsy, an invasive and costly procedure. The company has developed a simple blood test to be used for NASH diagnosis. An early diag-nosis seems to be the best way to stop the progression of the dis-ease by changing their life style and monitoring patient evolution.

main advantageS

The less complex, more quantitative, biochemically specific me-tabolomics approach is proving advantageous over rival technol-ogies such as genomics, transcriptomics and proteomics and is growing rapidly in an increasing range of fields such as disease diagnosis, drug development, plant science, and nutrition.

Nowadays one of the main strategies in metabolomics fields are metabolic profiles, that stand out as the foundation for changes produced during disease progression, drug action mechanism or nutrition effects on biological and pathological processes.

applicability of the technology

Metabolomics is increasingly being used in a variety of health applications including pharmacology, pre-clinical drug trials, toxicology, transplant monitoring, newborn screening and clinical chemistry.

Metabolomics, or metabolic profiling, is an emerging branch of genetic research that uses metabolites as very sensitive reporters to:

• Detect tiny changes or mutations that happen to genes or proteins

Technology Offers · HealTH 91

Page 92: Biotechnology Basque Country

• Monitor and/or measure the larger-scale physiological changes that occur in response to subtle changes in the environment.

• Assist in the improved monitoring of adverse drug reactions (so-called drug allergies).

Metabolomics, offers the best and most direct measure of physiological activity. It is a perfect vehicle for exploring any system that fundamentally relies on a biochemical foundation.

• Biomarker Discovery

• Pharmaceutical Discovery

• Drug Development

• Lead Optimization

• Bioprocessing Optimization

• Media Optimization

• Physiological Exploration

• Disease Diagnostics

• Agricultural Improvements

• Food and Diet Evaluation

• Toxicology Studies

current Stage of development

The metabolomics laboratory is up and running. Our company has already marketed the first Metabolomics based diagnostic test for Steatosis and NASH.OWL is also developing other diagnostic products for other high prevalence diseases, based in its metabolomics expertise.

On the other hand, the company has a wide range of Metabolomics services (OWL Lipids, OWL Skin…) to provide our customer with highly specialized Metabolomics

collaboration type

OWL Metabolomics Service is currently establishing itself in disease treatment and pharmaceutical and biotech research. The technology platform is optimally suited to provide high flexibility for services in other areas of applications such as nutritional and cosmetics.

In particular the technology platform is offered for services and contract research to accelerate and add value to our partners business in the following areas: development of metabolomic markers, clinical studies, diagnostic, toxicology, food analysis, plant analysis, process analytic and optimisation.

Other individual collaborations are also invited.

On the other hand OWL is also searching for partners (biotechnology or pharmaceutical companies) to reach commercialization agreements to extend its diagnostic products worldwide.

92 Technology Offers · HealTH

Page 93: Biotechnology Basque Country

Technology Offers · HealTH 93

Page 94: Biotechnology Basque Country

abStract of technology to exploit

Praxis Biopharma offers the infrastructure and staff required to research, develop and /or produce different pharmaceutical products, especially those of biological origin. The company has recently incorporated innovative laboratories in its GMP premises with miniaturized machinery and eco-innovative processes, particularly with an innovative LCA (Life Cycle Analysis) tool for pharmaceutical companies. Biopharma also offers nanoformulation processes, form research to GMP production and therapeutics based on lipid membrane technology.

deScription

Praxis Biopharma offers technological cooperation in several steps of pharmaceutical development, from R&D to production of pilot lots according to GMP rules. The main addressed lines are biologics (proteins like growth factors), lipid membrane therapy for rare cancers and nanoformulation of APIs to obtain new drugs. All the production steps follow GMP rules and quality control standards.

innovative aSpectS

Main innovative aspects are based on the innovation model of-fered by Biopharma, based on Open innovation concepts, aiming in share knowledge, technology, business, markets...Regard-ing technology, the team has high skills in R&D an innovative production processes, including production of sterile biologics and nanoformulations. Lipid membrane therapy is an innova-tive approach to treatment of diseases like rare, bad prognosis cancers, Alzheimer, pain, etc

promoter organization identification

organization name Praxis Biopharma Research Institute

contact Eusebio Gainza, R&D Manager

email [email protected]

phone +34 945 298198; +34 670 498195

fax +34 945 255215

description of the organization

Praxis Biopharma was established in 2008 with the aim of gathering the R&D activities in new medicines of an important pharmaceutical group (Praxis Group). The company is located in Vitoria in a facilities area of 3000 m2.

activity Pharmaceutical developments, pilot lots, nanoformulation

markets tackled Pharmaceutical developments, pilot lots, nanoformulation

Size 15 employees

Pharmaceutical products development and production

94 Technology Offers · HealTH

Page 95: Biotechnology Basque Country

main advantageS

• R&D supported by a skilled team which will help partners to reach new pharma products.

• Adequate size to produce tailor made lots for clinical trials.

• Possibility to produce nanopharmaceuticals for clinical investigation.

• Development of medicines through an innovative methodology that respects the three dimensions of sustainability with the help of an LCA tool customized for the pharmaceutical industry.

applicability of the technology

The technologies offered mainly address pharmaceuticals and medical products. Technologies will be useful to produce pilot lots with the required quality, although small batches. Nanoformulation makes possible to diminish side effects and increase efficacy, and is helpful for repurposing of drugs. Lipid membrane based therapies will contribute to develop novel drugs for cancer, Alzheimer, inflammation and pain.

current Stage of development

Commercial stage.

exploitation of rtd reSultS

Most of the offered technologies are result of national or international collaboration, including European and Latin American partners.

intellectual property rightS

Most of the offered technologies are covered by patents or licenses.

collaboration type

Research and Development, Fabrication, Commercial agreements

Technology Offers · HealTH 95

Page 96: Biotechnology Basque Country

abStract of technology to exploit

Praxis Pharmaceutical offers the infrastructure and staff required to develop, produce and/or distribute different pharmaceutical products, especially biologics and those related to regenerative medicine and rare diseases, niche markets.

deScription

Praxis is a leading Contract Development and Manufacturing Organization (CDMO) partner, specialized in providing develop-ment and small/medium scale aseptic processing and lyophili-zation manufacturing services for clinical batches. The company offers an integral service from the Development and the GMP Manufacture, up to the commercial supply of high value sterile drugs. Our flexible designed facilities are ideal for new products and small batches.

Praxis Pharmaceutical also offers research and commercial co-operation in several steps of pharmaceutical business, including research, development and distribution through our commercial division. The main addressed lines are regenerative medicine, including advanced therapies, growth factor based therapies, and medical, no pharmaceutical products (i.e. active dressing) and rare diseases, including products for Cystic Fibrosis (in-haled antibiotics, muco clearers, food supplements).

innovative aSpectS

Main innovative aspects are based on the innovation model of-fered by Praxis Pharamceutical, based on Open innovation con-cepts, aiming in share knowledge, technology, business, mar-kets...Regarding technology, in our new facilities, equipped with

promoter organization identification

organization name Praxis Pharmaceutical

contact Alfredo Gómez

email [email protected]

phone +34 945 298198

fax +34 945 255215

description of the organization

Praxis Pharmaceutical was established in 2006 with the aim of developing, produce and distribute novel medicines in the fields of regenerative medicine, rare diseases and cancer.

activity Development, production and distribution of drugs for regenerative medicine (wounds, ulcers, skin), rare diseases (Cystic Fibrosis, FH-Cholesterolaemia,…), and rare types of cancer, from own developments or from third parties.

markets tackled Pharmaceutical developments, production and distribution

Size 60 employees

Pharmaceutical products production and distribution

96 Technology Offers · HealTH

Page 97: Biotechnology Basque Country

the latest technologies, we offer the development and manufac-turing of sterile innovative drugs.

main advantageS

• Development supported by a skilled team which will help partners to reach new pharma products

• Expertise in aseptic processing and lyophilization of biologics and small molecules incorporating extensive knowledge of international requirements to meet the most demanding quality standards and customer needs.

• Analytics development for biologics and small molecules (HPLC, IEC, SEC-HPLC, SDS-PAGE, Bradford, etc.)

• We have more extensive experience working with complex substances such as biologics, including monoclonal antibodies, DNA, RNA derivatives, peptides and other proteins.

• Pilot scale plant with freeze drying unit available, lyophilization cycle optimization, as well as stability, clinical and validation batches and previous physico-chemical characterization.

• Own distribution network in Spain, Latin America, Portugal and France, to exploit developed products or licensed ones.

applicability of the technology

The technologies offered mainly address pharmaceuticals and medical products. Technologies will be useful to produce pilot lots with the required quality, although small batches, innovative business models will help to establish alliances, licenses etc, with interested partners.

current Stage of development

Commercial stage.

exploitation of rtd reSultS

Most of the offered technologies and innovative approaches are result of national or international collaboration, including European and Latin American partners

intellectual property rightS

Most of the offered technologies are covered by patents or li-censes.

collaboration type

Research and Development, Manufacturing, Commercial agreements, Licensing, Commercial distribution

Technology Offers · HealTH 97

Page 98: Biotechnology Basque Country

abStract of technology to exploit

The Functional Genomics Department at Progenika Biopharma specializes in providing customers with a complete and integrat-ed set of tailor made genomics services of the utmost quality, ranging from experimentation design to bioinformatics analysis and interpretation of the results obtained, together with experi-enced technical counselling throughout the entire project, from beginning to end.

deScription

The Functional Genomics Department at Progenika Biopharma offers scientists and researchers from pharmaceutical multina-tionals, R&D centers, hospitals and technological research insti-tutions worldwide the latest technologic approach and its expe-rienced know-how for projects on the following areas:

• Gene Expression. Full genome approach using microarrays or custom gene expression analysis using TaqMan technology.

• Genotyping, Full genome approach (GWAS) using microarrays or custom genotyping analysis using TaqMan, Kaspar or Golden Gate Illumina technology.

• Next Generation Sequencing. Illumina technology allows a variety of applications: Custom Resequencing, RNAseq, de novo DNA Sequencing, ChIPseq.

Progenika Biopharma is also Service Provider for Affymetrix Gene-Chip® technology in Spain since 2001. The Functional Genom-ics Department at Progenika process all arrays commercialised by Affymetrix, including both, catalogue and custom arrays. Affy-metrix DNA Analysis Arrays allow thousands of genotypes to be

promoter organization identification

organization name Progenika Biopharma. A GRIFOLS Company.

contact Borja Orbegozo. Customer Services Manager.

email [email protected]

phone +34 94 406 45 25

fax +34 94 406 45 26

description of the organization

Biotechnological company belonging to the Diagnostic Division of GRIFOLS.

activity Genomics Services.

markets tackled Biotech industry, Pharmaceutical laboratories industry, Research & Develpment Centers, Technological Institutions, universities, and Hospitals.

Size 90 employees

Functional genomics services

98 Technology Offers · HealTH

Page 99: Biotechnology Basque Country

determined simultaneously based on SNP (Single Nucleotide Poly-morphism) profiles in order to generate genetic fingerprint.

innovative aSpectS

Since its founding, back in 2000, Progenika Biopharma has been consistently committed to offering the most technologically ad-vanced services that the research community demands. The technological offerings we place at our customers fingertips are strengthened by highly qualified and experienced personnel, next generation equipment and high-performance laboratories and fa-cilities that are aligned with top GLP Quality Standards (Good Laboratory Practices).

main advantageS

The experienced personnel at Progenika can help scientists ac-complish their projects by providing counseling and technical ad-vice at every step of the process: experimental design, sample preparation, sample processing, sample quality and quantity and data analysis, in a tailor made approach.

The Functional Genomics team together with Progenika´s Bioin-formatics Support Group assists researchers with: data analysis and interpretation, statistical analysis, pattern recognition, and cluster analysis for turnkey projects.

applicability of the technology

The Functional Genomics Department offers its services to the Biotech industry, Pharmaceutical laboratories industry, Research & Development Centers, Technological Institutions, universities, and Hospitals.

current Stage of development

Functional Genomics Services are being offered today as an spe-cialized and customized service for top scientists and researchers worldwide.

intellectual property rightS

Functional Genomics Services are offered for research, so that Intellectual Property Rights remain on researcher that contract the service.

collaboration type

Genomics Services provider.

Progenika Biopharma´s Functional Genomics Department is a services provider and so its business relationships are customer- supplier.

Technology Offers · HealTH 99

Page 100: Biotechnology Basque Country

abStract of technology to exploit

Proteomika owns proprietary tests (Promonitor®) to monitor pharmacokinetics and immunogenicity of patients being treated with biological drugs. Analyses are performed on infliximab (Remicade®), adalimumab (Humira®), etanercept (Enbrel®) and rituximab (Mabthera®). The technology is based on validated ELISA immunoassays. The main utility of this technology is to support physicians in monitoring the response of the patient therefore to optimize the treatment regime and make a rational use of biological therapies. Proteomika can also support research as well as clinical development of new biopharmaceuticals by designing immunoassays to assess for immunogenicity of the drugs.

deScription

The Promonitor® series are tests for establishing both the concentration of biological drugs as well as the antibodies that are created by the patient against the drugs. Promonitor® al-lows for a sensitive and specific monitoring of the circulating levels of each drug and its immunogenicity, so that the doctor can evaluate these variables in order to have a closer moni-toring of the patient’s response to the treatment and to be able to take the therapeutically adequate decisions. The tests are based on ELISA technology and uses specific recombinant monoclonal antibodies.

innovative aSpectS

A major problem with biological drugs is that their bioavail-ability and immunogenicity change from patient to patient and within the same treatment. Immunogenicity is strongly cor-

promoter organization identification

organization name Proteomika , S.L.

contact Daniel Nagore

email [email protected]

phone +34 944 064525

fax +34 944 064526

description of the organization

Privately held biotechnological company

activity In vitro diagnostics

markets tackled Diagnostics of complex diseases and monitorization of response to treatments

Size <30

Monitoring of biological therapies

100 Technology Offers · HealTH

Page 101: Biotechnology Basque Country

related to a loss of clinical response to the treatment; therefore, the assessment of these biological variables can assist the phy-sician to select the best treatment, optimize the dosing, pre-vent for infusion reactions, and to make a rational use of such expensive therapies. This type of products and technologies are not easily accessible to rheumatologists and gastroenterologists. Proteomika has moved forward in the field in order to develop tests and services and to provide the medical communinity with these new tools. Promonitor® undergoes different clinical trials to validate the tests, therefore unlike other tests and services we have developed clinical guidelines and therapeutic decision algo-rithms based on the results for a straightforward interpretation.

main advantageS

The Promonitor® series offers outstanding sensitivity and spec-ificity, with technically and clinically validated immunoassays. Promonitor® is the perfect tool to monitor the treatment of pa-tients with biological drugs. Promonitor® know-how can be used to develop new assays to assess for immunogenicity of new drug developments. Promonitor® can also be adopted to demonstrate efficacy of biological drugs.

applicability of the technology

The Promonitor® series can be applied by public healthcare sys-tems to improve patient management, make a rational use of bi-ological therapies and associated costs. The Promonitor® series is a useful tool in clinical trials, and comparison and benchmark-ing studies to prove the efficacy of other biopharmaceuticals.

current Stage of development

Eight Promonitor® products have been developed and validated. All products are CE marked and started the commercialization in 2011.

exploitation of rtd reSultS

This is a proprietary R&D driven product.

intellectual property rightS

Intellectual property surrounding the product is fully owned by Proteomika.

collaboration type

Product distribution agreement is sought for any territory but Spain. Proteomika also offers immunoassay development and validation to pharma industry.

Technology Offers · HealTH 101

Page 102: Biotechnology Basque Country

abStract of technology to exploit

We have developed a set of proprietary technologies to transform the currently existing inert PEEK material into a bioactive PEEK material by changing its structure and surface properties. Our development deals with bioactive non-biodegradable polymer scaffolds, e.g. PEEK, with:

• Controlled multi-modal porosity for integration into and repair of bone tissue based on Thermally induced phase separation.

• Controlled bioactive surface based on the covalent bonding of biomimetic peptides using click chemistry.

Our aim is to find a company interested in applying our technologies to their PEEK products and to establish a stable collaboration and licensing agreement.

deScription

1. Technology: TIPS (Thermally Induced Phase Separation) to produce porous foams on PEEK, as well as hybrid porous-dense PEEK materials. The aim is to mimic bone structure to improve the material biointegration and to obtain also a shock absorbing material.

2. Technology: Click chemistry on PEEK Surface using biomimetic peptides. The aim is to active PEEK surface to improve osteoblast adhesion and proliferation. The main advantage is to improve chemical reactivity of the surface to biological entities to anchor biomolecules on the surface of bone implants

promoter organization identification

organization name TECNALIA

contact Jesus Valero

email [email protected]

phone + 34 606227330

fax -

description of the organization

Private non for profit Research Organization

activity Research

markets tackled Health

Size 1.400 employees

Bioactive PEEK

102 Technology Offers · HealTH

Page 103: Biotechnology Basque Country

innovative aSpectS

• Improved biointegration

• Shock absorbing material for spine applications

• Tunning of mechanical properties

main advantageS

The main advantages of the technology are:

• The possibility of achieving scaffolds with customized micro and sub-micro geometry.

• Incorporation of bioactivity to dense and porous PEEK materials.

• Possibility of applying the technology to bio-inert polymers, e.g. PEEK.

applicability of the technology

The technology can be applied into implants and scaffolds, especially those applied in the orthopaedics field. Likewise, the technology could be applied in other fields where a multi-modal porosity is required.

current Stage of development

Prototypes produced with the technology are available upon request. Extensive preclinical studies, in selected animal models are in process. A full set of in vitro and vivo testing data will be available in 2014.

exploitation of rtd reSultS

Porous PEEK is the result of a proprietary development of Tecnalia,

who owns 100% of the property rights. Biomimmetic surfaces are the result of a join collaboration of Tecanlia, CIBER-BBN and UPV-EHU.

intellectual property rightS

3 existing patents protecting the technologies:

Patent EP 2338532. Pororus PEEK article as an implant. Priority date: 23/12/09. A porous PEEK-type polymer article comprising a porous Peek-type polymer structure and presenting at least a trimodal pore distribution as follows:...

Patent EP 12382535.8. A 1,4,5-trisubstituted 1,2,3-triazole mimetic of RGD and/or OGP10-14, process to obtain it and uses thereof.

Patent EP 12382534.1. Modified polyaryletherketone polymer (PAEK) and process to obtain it.

collaboration type

TECNALIA is looking for licensing this technology, either at this stage of development, or alternatively entering in to further co-development agreements with other partners.

Technology Offers · HealTH 103

Page 104: Biotechnology Basque Country

promoter organization identification

organization name Enzyme and Cell Technology Group, university of the Basque Country (uPV/EHu), Faculty of Science and Technology, Department of Biochemistry and Molecular Biology

contact Juan L. Serra

email [email protected]

phone (+34) 94 601 2541 (Office) & (+34) 94 601 5417 (Lab)

fax (+34) 94 601 3500

description of the organization

Public university

activity Academia and Research

markets tackled -

Size -

abStract of technology to exploit

The main goal of the Enzyme and Cell Technology Group is the use and development of nanotechnologies which employ biocatalysts (isolated enzymes or microbial cells) for industrial, environmental or biomedical applications. For this purpose we have recently prepared two robust magnetically-separable types of nanobiocatalysts by binding either soluble enzymes onto the surface of magnetic nanoparticles (MNPs) or by cross-linking aggregates of enzymes (CLEAs) among them and to MNPs to obtain magnetic CLEAs (mCLEAs). These novel magnetic biocatalysts can be of interest in industrial biotechnology and biomedicine.

deScription

The use of immobilized enzymes in industrial applications often presents advantages over their soluble counterparts, mainly in view of stability, reusability and simpler operational processing. Because of their singular properties, such as biocompatibility, large and modifiable surface and easy recovery, iron oxide magnetic nanoparticles (MNPs) are attractive super-paramagnetic materials that serve as a support for enzyme immobilization and facilitate separations by applying an external magnetic field. Cross-linked enzyme aggregates (CLEAs) have several benefits in the context of industrial applications since they can be cheaply and easily prepared from unpurified enzyme extracts and show improved storage and operational stability against denaturation by heat and organic solvents.

innovative aSpectS

Our data reveal that the combination of cross-linked enzyme aggregates (CLEAs) with MNPs results in a robust magnetic

Preparation of magnetic biocatalysts and its uses in industry and biomedicine

104 Technology Offers · HealTH

Page 105: Biotechnology Basque Country

biocatalyst which is able to catalyze the synthesis of biodiesel (for example) at low biocatalyst concentration, and is more stable than other lipase preparations reported so far.

main advantageS

The robust magnetic biocatalyst obtained combines the relevant catalytic properties of CLEAs (as great stability and feasibility for their reutilization) and the magnetic character of MNPs, and thus the final product (mCLEAs) are superparamagnetic particles of a robust catalyst which is more stable than the free enzyme, easily recoverable from the reaction medium and reusable for new catalytic cycles.

applicability of the technology

We have prepared mCLEAs of lipases to catalyze transesterification reactions to produce biodiesel and biosurfactants as well as polyhydroxyalkanoate depolymerases, enzymes capable to degrade bioplastics in order to obtain chiral monomers of (R)-3-hydroxyoctanoic acid or furane-derived oligoesters of interest in fine chemical, pharmaceutical and biomedical industries.

We have studied the main properties of our magnetic biocatalysts of lipase and we have assessed its utility to catalyze transesterification reactions to obtain biodiesel from non-edible vegetable oils including unrefined soybean, jatropha and cameline, as well as waste frying oil. using 1% mCLEAs (w/w of oil) conversions up to 99% were obtained after 72 h at 30ºC. Moreover, the magnetic biocatalyst can be easily recovered from the reaction mixture and reused at least for fifty consecutive cycles of 24 h without apparent loss of activity. The obtained results suggest that mCLEAs prepared from CALB can become a powerful biocatalyst for application at industrial scale with better performances than those available nowadays.

A similar procedure to that detailed here to prepare mCLEAs of CALB can be easily expanded to prepare mCLEAs of other enzymes of interest.

current Stage of development

The technology is available to obtain magnetic biocatalysts from any enzyme at laboratory scale

exploitation of rtd reSultS

The development of our magnetic biocatalysts have been done during the implementation of national (MINECO CTQ2011-25052 and SAIOTEK S-PE12UN041) and European (ENERGREEN EFA217/11) projects

intellectual property rightS

The intellectual property rights are designed and agreed for each specific collaboration.

collaboration type

Open to all type of collaboration with industry, research centres or universities.

Technology Offers · HealTH 105

Page 106: Biotechnology Basque Country

abStract of technology to exploit

The two business lines of Vacunek are the development of efficacious vaccines against animal mycobacteriosis in cattle and wildlife species and the production and commercialization of robust diagnostic tools for animal and plant diseases.

Regarding diagnostic tools Vacunek has the following working units:

• Production and customized design of multiple NAATs (PCR based) diagnostic tests.

• Production and development of enzyme immunoassays (EIA) tests.

• Protein Expression System Service (Escherichia coli, Mycobacterium smegmatis).

deScription

Vacunek is a SME, Spin-off from the Basque Institute for Agrar-ian Research and Development (NEIKER-Tecnalia), focused on the application of new biotechnology tools for animal health. Our main expertise relates to infectious diseases of animals and, spe-cifically, production animals.

We are opened to cooperation in terms of offering our portfolio of diagnostic methods for selling in collaborator’s country. OEM production is also considered.

innovative aSpectS

• Improved vaccines against Mycobacterium to be used in cattle, particularly Mycobacterium avium subsp. paratuberculosis, pur-sue the absence of interfere with tuberculosis skin test.

• Vacunek provides for recombinant mycobacterial antigens ex-pression optimized and specific mycobaterial expression system (M. smegmatis) as well as E. coli system.

• Vacunek offers technical solutions including design, develop-

promoter organization identification

organization name VACuNEK, S.L.

contact Beatriz Lázaro

email [email protected]

phone +34 946 573565; +34 615 700036

fax +34 944 030609

description of the organization

Spin-off from the Basque Institute for Agrarian Research and Development (NEIKER-Tecnalia)

activity Animal health products (vaccines prototypes, diagnostic kits and diagnostic services)

markets tackled Veterinary diagnostic laboratories, research centres, molecular biology and biotechnology, universities, clinical veterinarians, agri-food industry

Size SME

Developing novel vaccines for animal mycobacteriosis and nucleic acid amplification tests (NAATs) for animal diseases

106 Technology Offers · HealTH

Page 107: Biotechnology Basque Country

ment and optimization of customized (singleplex, multiplex) PCR assays and specific enzyme immunoassays in a broad area of fields (animal diseases with special consideration to bovine mastitis, plant diseases, processed animal proteins (PAPs)). Robust PCR-based assays, predominantly Real Time, and personalized and cus-tomized follow-up is provided by our technical services.

main advantageS

Detection of pathogens that produce animal diseases using PCR can offer higher speed and specificity than traditional immunological based assays. In addition, if the PCR is Real Time based, possible problems of contamination can readily be eliminated in diagnostic laboratory conditions. Furthermore, Real Time PCR permits high throughput analyses of samples and quicker results for customers. Real Time PCR kits overcome the limitations of traditional PCR, as this technology allows the detection of PCR amplification dur-ing the early phases of the reaction. The new fluorescence based techniques can also be used for quantization of the pathogen in samples besides pathogen detection.

applicability of the technology

Vacunek offers a range of products that can be used by research-ers and manufacturers of diagnostic assays or vaccine prototypes in the field of animal and plant diseases.

Additionally, we offer technical solutions including design, development and optimization of customized PCR assays in a broader field of interest (fast and reliable identification of mastitis causing bacteria from bovine milk, animal feed, identification of animal species, agri-food).

current Stage of development

Vacunek offers a wide range of products for identification of pathogens that produce diseases in livestock and companion

animals and plant diseases. Diagnostic kits are ready for distribution within the UE market. Kits are for research use purposes only.

All techniques offered are appropriately developed following the scientific literature and standardized and validated within Animal Health and Production Department of Neiker-Tecnalia. Vacunek has experience in validation studies for both diagnostic tools (PCR and ELISA) as well as registration in Spanish autorities specific for Veterinary (Ministry of the Enviroment and Rural and Marine Affairs).

Vacunek has strong alliances with four internationally-recognised diagnostic companies.

exploitation of rtd reSultS

Vacunek is a spin-off from a Research Center, Neiker-Tecnalia, and thus, our products are the result of years of research and experience from multiple projects at Neiker-Tecnalia. Researchers at this centre have more than 25 years of experience working on paratuberculosis and bovine tuberculosis and on the diagnosis of animal diseases. Vacunek is also collaborating with other companies dedicated to the manufacture of veterinary drugs and biologicals.

intellectual property rightS

The intellectual property rights are designed and agreed for each specific collaboration.

collaboration type

Vacunek is open to research and commercial agreements through joint ventures, licenses, participation in next calls from Eu pro-grams, etc. We are also interested in agreements to sell or produce diagnostic kits for animal diseases, preferably PCR-based. We offer our technology and expertise to animal health centres who wish to develop specific diagnostic tools.

Technology Offers · HealTH 107

Page 108: Biotechnology Basque Country

abStract of technology to exploit

Vicomtech-IK4 develops innovative solution based on the following technologies:

• Computer Visualization: includes the computer-supported methods and techniques to represent information of any kind using visual metaphor, such as all kinds of 2D images and diagrams (that can be either static or interactive), various forms of 3D representations (volumetric, surface-based, point-based, etc.), and interactive and dynamic visual simulation of complex phenomena, etc.

• Image processing: a form of signal processing of images or video frames and their low-level processing for extracting certain characteristics or parameters, or synthesizing new processed images as an output. In a broader sense, Computer Vision can be seen as a more generic form of image processing, closer to Image understanding, in which the goal is to process, understand and decipher characteristics or track objects in an image or sequence of video images, with a clear goal in mind.

• Knowledge Discovery & Data Mining (KDD): these techniques focus on the computer-supported extraction of useful knowledge from data and information. They help to discover and identify patterns in data that are hidden, not evident –and sometimes unexpected-, making them understandable. The use of KDD in biomedical-based applications is a powerful mechanism for improving understanding and adding value to large, multimodal repositories of biomedical information.

Computer Graphics, Visual Computing and IT Solutions for the Processing, Analysis and Visualization of Biomedical Data and Knowledge

promoter organization identification

organization name Fundación Vicomtech-IK4

contact Iván Macia

email [email protected]

phone +[34] 943 30 92 30

fax +[34] 943 30 93 93

description of the organization

Vicomtech-IK4 is an applied research centre specialised in Computer Graphics, Visual Computing and Multimedia technologies, founded in 2001 and based at San Sebastián Technology Park

activity Vicomtech-IK4’s eHealth and Biomedical Applications department is focused on Research and Development of graphics and computer vision technologies for the medical, clinical, health, biology, biotechnology and pharmaceutical sectors. Its main lines of research include the latest techniques in image processing, data visualization, advanced interfaces and biomedical information management.

markets tackled Biomedical and pharmaceutical markets, healthcare organizations

Size 120 employees

108 Technology Offers · HealTH

Page 109: Biotechnology Basque Country

deScription

Vicomtech-IK4 is focusing its research on aspects of Computer Visualization, such as:

• Advanced Visualization: including 2D/3D visualization and advanced renderings of images, volumes and complex datasets.

• Visual Analytics allows the analytical reasoning of complex data facilitated by interactive visual interfaces.

• Modelling and Simulation in which complex models of processes of engineering and science can be analyzed and interactively visualized.

Vicomtech-IK4 is also focusing its research on important aspects of Biomedical Image Processing for different imaging modalities, including most medical imaging modalities (MR, CT, uS, RX…) and biological images (microscopy, electrophoresis gels), such as:

• Image Fusion and Registration provides the alignment and correlation of different images and image types to synthesize new combined images with enriched information.

• Segmentation provides a way to identify and isolate regions of interest or specific structures in images in order to focus the analysis on these areas, as for instance in biomedical imaging.

• Feature Extraction allows reducing the complexity (dimensionality) of an image by transforming the input data into a set of features that display relevant characteristics of the image.

• Object Tracking is used to follow the position of an object

using Computer Vision or other techniques, to precisely determine its relative position and motion.

Vicomtech-IK4, in the same, way focuses its research on Knowl-edge Discovery & Data Mining technologies, such as:

• Semantic technologies provide the means for modelling the knowledge of a domain and the execution of reasoning processes over such domain for knowledge discovery.

• Ontologies explicitly specify the conceptualization of a knowledge domain, allowing the description of its elements and relationships in a way that can be reused by different applications or during the modelling of a different domain.

• Clinical Decision Support Systems provide decision recommendations based on criteria embedded in the system, which follow evidence of biomedical bibliographic resources or clinical guidelines and protocols.

• Experience-based reasoning allows the updating of decision criteria with the daily experience acquired by the biomedical professionals.

• Classifiers and other Pattern Recognition technologies allow classifying information into coherent sets in a supervised or unsupervised manner.

innovative aSpectS

Our position as applied research centre, in close contact with ba-sic research institutions and in close collaboration with the indus-try, allows us to provide practical solutions with advanced tech-nologies that in many cases go beyond the state-of-art in each of

Technology Offers · HealTH 109

Page 110: Biotechnology Basque Country

the described technologies.

These technologies in general allow the improvement of work-flows, internal processes, production or development related costs, the automation of tasks, as well as the combination of mul-timodal information for the discovery of patterns and new knowl-edge, and the reuse of existing knowledge and experience in an organization.

The development process of such technologies follows internation-al quality standards on R&D management, to which Vicomtech-IK4 is committed. In fact, Vicomtech-IK4 is one of the first centres holding both, the ISO 9001:2008 and uNE 166002:2006 research quality certificates.

main advantageS

We provide custom solutions based on the above innovative tech-nologies, with a clear commitment to develop new or improved products/services, as well as to improve internal processes, in order to position companies more competitively in the current market and industrial landscape.

applicability of the technology

The technologies presented have been implemented in several solutions developed within local, national and European projects. Following examples present solutions developed in Vicomtech-IK4 within the biomedical and/or pharmaceutical fields:

• Solutions for the management of clinical trials and studies: Vicomtech-IK4 developed biomedical research-oriented platforms, providing multimodal data integration, the discovery of new knowledge and patterns, the management and reuse of previous experiences, and advanced interfaces and data sharing that facilitate multicentre approaches.

• Solution for biological in-vitro assays analysis: Vicomtech-IK4 develops solutions for High Screening Content analysis, with automatization of image processing, feature extraction and result analysis with dramatic acceleration of the analysis workflow.

• Electrophoresis: Vicomtech-IK4 developed a solution for the analysis of electrophoresis gel for accurate protein detection.

• Metabolomic pathway visualisation: Vicomtech-IK4 developed a web-based solution that allows metabolomic pathway simulation and analysis, visualization or comparison of various metabolomic pathways.

current Stage of development

Vicomtech-IK4 is developing different R&D solutions and is orienting the development into industrial applications. Some of the presented technologies are ready-to-use and others are in a prototype stage. Customisation of the presented solutions may be required following the application fields targeted.

intellectual property rightS

The intellectual property rights are established and agreed for each collaboration, according to the specific needs and requirements.

collaboration type

Vicomtech-IK4 is interested in collaborating with biotech and pharmaceutical companies interested in incorporating its technol-ogy-based solutions into their products, services or processes. It is also interested in collaborating with technological or clini-cal partners (hospitals, research centres, universities, etc) in the frame of projects that aims at developing cutting-edge technolo-gies for clinical and industrial applications.

110 Technology Offers · HealTH

Page 111: Biotechnology Basque Country

Technology Offers · HealTH 111

Page 112: Biotechnology Basque Country

112

Page 113: Biotechnology Basque Country

Technology Offers

Agri-food

113

Page 114: Biotechnology Basque Country

abStract of technology to exploit

Biofungitek is a company specialized in the development and sales / distribution of chemical fungicides of natural origin, for fungi diseases control in agricultural crops, post-harvest, food storage and other industrial disinfectants, as well as efficient plant strengtheners that increase crop tolerance.

deScription

BIOFuNGITEK has the intellectual property of a new technol-ogy which allows identification and selection of new chemical compounds that control specific fungi growth and development, suitable for conventional IPM and/or organic farming

Our range of fungicides offers:

• Effective and specific solutions for each fungus.

• Avoids the emergency of chemical resistance.

• Safety for the environment, workers and consumers.

• It does not affect life cycles of other organisms, including beneficial insects and bees.

BIOFUNGITEK also works analyzing fungicidal mode of action of commercial pesticides and their improvement through combina-tion with chemical compounds of our portfolio with a synergistic fungicide effect. We offer innovative solutions that increase ef-ficacy of fungicides and guarantee crop care and quality.

innovative aSpectS

BIOFUNGITEK is specialized in:

promoter organization identification

organization name BIOFuNGITEK, S.L.

contact Javier Fernández-Anero

email [email protected]

phone +34 946 120 284

fax +34 944 030 609

description of the organization

Technological based Private Company

activity Biofungitek is a company specialized in the development and Sales / Distribution of chemical fungicides and biostimulants of natural origin.

markets tackled Food industry, agriculture, agrochemicals

Size Small enterprise

Fungicide and biostimulant products for control of main agricultural fungal disease

114 Technology Offers · AGRI-FOOD

Page 115: Biotechnology Basque Country

• Obtaining active substances through our exclusive Technology.

• Developing new fungicides with our own methodology.

• The main fungi and bacteria responsible for the most severe crops fungi pests (Botrytis cinerea, Powdery Mildew, Downy Mildew, Penicillium digitatum, Fusarium oxysporum, Alternaria alternata…).

main advantageS

The formulations developed by BIOFuNGITEK guarantee:

• Efficacy

• Innovation

• Natural origin

• User and environment safety

• Decrease in pest resistance & pesticide residue risk

applicability of the technology

BIOFUNGITEK’s catalogue includes:

• Efficient plan strengtheners that increase crop tolerance against harmful fungi and bacteria.

• Product mending and replacing: Enhancement of matured fungicidal products, dose reduction, etc

• Food storage and transport warehouses disinfectants.

current Stage of development

BIOFuNGITEK is developing several products at the moment. Some of these products are still at a level of research, development and

field testing validation. Other products are in commercial stage.

exploitation of rtd reSultS

BIOFUNGITEK’s range of products is based on the wide experience of our own technical team in the fungi research and the know-how gained thanks to years of work in R&D developments.

intellectual property rightS

BIOFuNGITEK owns the intellectual property of its range of products.

collaboration type

BIOFuNGITEK is open to research and commercial agreements through joint ventures, licenses, participation in next calls from Eu programs, etc.

Technology Offers · AGRI-FOOD 115

Page 116: Biotechnology Basque Country

abStract of technology to exploit

Electrospinning of microfibres is very well developed for polymers. We moved the knowledge and the processes to food, creating new tastes and appearances of known foodstuff.

deScription

Electrospinning is very well developed for polymers, but not for biomolecules such as sugars or proteins. We have gained considerable experience with protein solutions, and recently tested also liquid foodstuff such as caramel or honey. In addi-tion, we have acquired knowledge on simple blending of vari-ous substances. We are thus confident to apply our technogy to a wide variety of food.

Electrospinning results in a highly porous mesh of fibres, po-tentially with new tastes to explore. Moreover, the fibres are barely visible, which allows for new visual experiences.

Alternatively, electrospinning sprays food over an area of up to 1 ft across, in ultrafine distribution, and can thus improve homogenous coatings.

innovative aSpectS

New tastes: Conventional techniques end up with conventional, known tastes.

Optical aspects: Creation of nearly invisible food, e.g. for specialities.

Food coatings: Ultrafine distribution.

promoter organization identification

organization name CIC nanoGuNE

contact Alexander Bittner

email [email protected]

phone +34943574000

fax +34943574001

description of the organization

CIC Nanogune is a center created with the mission of addressing basic and applied world-class research in nanoscience and nanotechnology, fostering high-standard training and education of researchers in this field, and promoting the cooperation among the different agents in the Basque Science, Technology, and Innovation Network (Universities and Technological Centers) and between these agents and the industrial sector. Nanogune develops the Cooperative Research Center (CIC) concept, which has been successfully implemented in various cases in the Basque Country.

activity Basic Research and nanotechnology

markets tackled Food

Size ca. 100

Spun food

116 Technology Offers · AGRI-FOOD

Page 117: Biotechnology Basque Country

main advantageS

• New tastes of well-known food

• Near-invisible forms of food

applicability of the technology

Sector: Food industry, speciality restaurants.

Problems that can be solved: Highly homogeneous distribution of food (micro and nanofibres); exploration of new tastes.

current Stage of development

Prototype.

collaboration type

Joint development of production tool, e.g. under a co-develop-ment agreement.

Technology Offers · AGRI-FOOD 117

Page 118: Biotechnology Basque Country

abStract of technology to exploit

Biolan develops and manufactures amperometric biosensors based on enzymes produced by the company. BIOLAN has oriented the R&D towards the development of new biosensors to measure different parameters of interest to the agrofood market as histamine, lactose sulphites, etc and different biomarkers for the health industry.

deScription

A biosensor is an analytic compact equipment which uses the biological interactions to give quantitative results.

Biolan develops biosensor for the determination of parameters with great importance in the agrofood industry as histamine, lactose or sulphites. The biosensors are based on enzymes pro-duce by the company. The production itself gives added value to the biosensors, allowing BIOLAN to adapt enzymes to the needs of development in terms of stability and reproducibility.

The detection level reaches ppm using a potentiostatic, a high sensitivity detector also develop by the company.

Initially, developments have been focused exclusively on qual-ity control of musts and wines with Biosensors for detection of gluconic acid, fructose/glucose and malic acid. At present Bio-lan manufacturates biosensor for detection of histamine in fish and lactose in lactose free products redirecting the efforts of the company to the broad agrofood industry.

promoter organization identification

organization name BIOLAN MICROBIOSENSORES S.L.

contact Arrate Jaureguibeitia

email -

phone +34 946 574 161

fax + 34 946 574 164

description of the organization

Biolan is a biotechnological company focused on the development of biosensors with application on such as the food industry or human health.

activity Biolan is a biotechnological company which develops, manufactures and commercializes biosensors for measuring in real time

markets tackled Agro food industry and Health industry

Size SME

Biosensors for the agro-food industry

118 Technology Offers · AGRI-FOOD

Page 119: Biotechnology Basque Country

innovative aSpectS

In the agrofood industry it is of great importance the monitorization of key parameters for quality and safety control. Actually the detection methods implanted in the food industries are expensive and time consuming. The companies are demanding a low cost, fast and effective technology for the quantification of key parameters at real time. The biosensoric technology of Biolan complies with all these requirements.

• Precise.

• Repeatable.

• Disposable.

• Inexpensive

main advantageS

The advantages which this technology offers are:

• Specificity

• High sensibility

• High speed reply

• Simplicity in its implementation

• Possibility to monitoring in continuous

• Integration in automated systmes

• Capacity to work in real-time

• Versatility

applicability of the technology

This technology is applied in the agro food industry for the

quantification of parameters related to quality control and safety assurance.

current Stage of development

Biolan has achieved the development of biosensor for quantification of gluconic acid, malic acid, glucose, fermentable sugar, sucrose for the wine sector, histamine for the fishery sector and glucose and lactose for the dairy sector.

Actually the company is working for the development of enzymatic sensors for sulphite determination or inmunosensor for pathogen determination.

exploitation of rtd reSultS

Biolan was a spin off from Tecnalia, so our products are the result of years of research and experience from multiple projects at Tecnalia.

intellectual property rightS

Depending on the negotiation.

collaboration type

Biolan is open to research and commercial agreements through joint ventures, licenses, participation in European programs, etc.

Technology Offers · AGRI-FOOD 119

Page 120: Biotechnology Basque Country

120

Page 121: Biotechnology Basque Country

Technology Requests

Health

121

Page 122: Biotechnology Basque Country

abStract of technology to exploit

We are looking for new and efficient specific biosensors, not based on fluorescent labelling or hybridization microarrays technology, with applicability in biotechnology, biomedicine, food and environmental control.

deScription

The molecules to be detected will be antibodies, ligand-binding proteins, natural or synthetic nucleic acids.

technical SpecificationS

• Analytical device of improved sensitivity and specificity.

• Quantitative detection.

• Stable, cheap and easy to synthesise.

marketS addreSSed:

Human diagnostic.

collaboration type:

Any.

kind of agreement Sought:

Any.

promoter organization identification

organization name GENETADI BIOTECH

contact José Luis Castrillo

email [email protected]

phone +34 944 044 343

fax +34 946 566 628

description of the organization

Private company

activity Development of new human genetic tests

markets tackled Diagnostic and prognostic of specific diseases

Size 12 employees

Biosensor Instruments for In-Vitro Diagnostic Testing

122 Technology Requests · HealTH

Page 123: Biotechnology Basque Country

abStract of technology to exploit

Recent advances in sequencing technology have increased the speed of data acquisition. However, without accompanying improvements in the ability to select relevant portions of the genome, i.e., specific chromosomal regions, or exons, the technology cannot achieve its full potential in studying the relationships between genes and diseases.

deScription

The aim of the present request is to develop new “in-vitro” and “in-vivo” methods to identify and isolate specific human DNA-regions previous to high-throughput DNA sequencing.

technical SpecificationS

We are looking for highly-specific technologies to “capture “ hu-man DNA in-solution.

marketS addreSSed:

Human diagnostic.

collaboration type:

Co-development, Licensing and acquisition.

kind of agreement Sought:

Exclusive and non-Exclusive.

promoter organization identification

organization name GENETADI BIOTECH

contact José Luis Castrillo

email [email protected]

phone +34 944 044 343

fax +34 946 566 628

description of the organization

Private company

activity Development of new human genetic tests

markets tackled Diagnostic and prognostic of specific diseases

Size 12 employees

Development of new “in-vitro” and “in-vivo” methods to identify and isolate specific human DNA-regions previous to high-throughput DNA sequencing

Technology Requests · HealTH 123

Page 124: Biotechnology Basque Country

promoter organization identification

organization name HISTOCELL

contact Julio Font

email [email protected]

phone +34 94 6567900

fax +34 94 4036999

description of the organization

Biotechnology company for cell therapy

activity Our company is focused on the research, development and production of new cell therapy and tissue engineering products for regenerative medicine

markets tackled Public and private hospitals, pharmaceutical companies, biotech companies.

Size 31 employees

New biomaterials for tissue engineering and cell therapy products

abStract of technology to exploit

Our company is looking for new biomaterials both of natural or synthetic origin that could be used as scaffolds for the development of new cell therapy or tissue engineering products.

deScription

The new biomaterials of interest for HISTOCELL could be both of natural or synthetic origin. In all cases, those biomaterials must be biodegradable, non-toxic for human and they should be sus-ceptible of being produced at low cost under GMP conditions. We are interested in different types of biomaterials depending on the final clinical use. HISTOCELL is especially interested in biomateri-als that could be used as scaffolds for one or more of its fourth research Programmes: bone regeneration, joint regeneration, wound healing and neuroscience.

technical SpecificationS

We are especially interested in new hydrogels sensitive to the temperature that could be used as inyectable biomaterials.

Other types of biomaterials are also of interest for the company if they could be used in cell therapy products for regenerative medicine.

marketS addreSSed:

Public and private health sector and pharmaceutical companies.

collaboration type:

Our company is interested in this technology of new biomaterials only in the case that can negotiate the patent or the license of the patent of such technology.

kind of agreement Sought:

HISTOCELL is open to negotiate different kinds of agreement for licensing or co-developing the requested technology.

124 Technology Requests · HealTH

Page 125: Biotechnology Basque Country

Bioreactors and large viral purification systems

abStract of technology to exploit

Inbiomed seeks collaboration with companies that manufacture bioreactors and large viral purification systems are sought for producing clinical quality viruses.

deScription

Inbiomed aims for getting the GMP certification for producing viruses for gene therapy. Collaboration with enterprises that manufacture bioreactors and large viral purification systems are sought (for lenti- and AAV viral vectors).

technical SpecificationS

Novel cutting-edge technologies that aid the upscaling of the viral production are sought (bioreactors and viral purifications systems).

marketS addreSSed:

Biotechnology industry, pharmaceutical industry.

collaboration type:

Any.

kind of agreement Sought:

Any.

promoter organization identification

organization name Inbiomed

contact Naiara Tejados

email [email protected]

phone +34 943309064

fax +94 943308222

description of the organization

Private foundation

activity Biomedical research and regenerative medicine

markets tackled Pharmaceutical, biotechnological

Size 27 employees

Technology Requests · HealTH 125

Page 126: Biotechnology Basque Country

Superesolution techniques/modules and long-term incubation modules for in vivo assays in confocal microscopy

abStract of technology to exploit

Inbiomed seeks collaboration with companies that develop Superesolution techniques/modules and long-term incubation modules for in vivo assays in confocal microscopy.

deScription

Inbiomed has a Cytometry and Advanced Optical Microscopy Core Facility that enables its users to carry out their experi-ments in confocal optical microscopy with the highest qual-ity standards (UNE-EN ISO 9001.2008). Collaboration with en-terprises that develops superesolution techniques/modules and long-term incubation modules for in vivo assays are sought.

technical SpecificationS

Superesolution techniques/modules and long-term incu-bation modules for in vivo assays are needed in the confocal microscopy service.

marketS addreSSed:

Biotechnology industry, pharmaceutical industry.

collaboration type:

Any.

kind of agreement Sought:

Any.

promoter organization identification

organization name Inbiomed

contact Naiara Tejados

email [email protected]

phone +34 943309064

fax +94 943308222

description of the organization

Private foundation

activity Biomedical research and regenerative medicine

markets tackled Pharmaceutical, biotechnological

Size 27 employees

126 Technology Requests · HealTH

Page 127: Biotechnology Basque Country

Genetically-Encoded Fluorescent Biosensors

abStract of technology to exploit

We are looking for genetically-encoded fluorescent biosensors that combine fluorescent proteins (FPs) and sensor proteins (SPs) fused in a specific way. They must to detect changes in fluorescence in response to the cell event of interest, due to binding or reaction with a target molecule.

marketS addreSSed:

Human diagnostic.

collaboration type:

Co-Development, Licensing and acquisition.

kind of agreement Sought:

Technology Transfer Agreement, Exclusive & Non-Exclusive.

promoter organization identification

organization name Innoprot

contact Jorge Gámiz

email [email protected]

phone +34 944005355

fax +34 946579925

description of the organization

Innoprot is a dynamic and R&D intensive biotech focused on developing cell-based assays for High-Throughput Screening and High-Content Analysis. Innoprot also acts as a CRO providing drug screening services and on-demand assay development. Our goal is to accelerate and improve our customer’s drug discovery programs.

activity Cell-based assays, Drug Screening, HTS, HCS

markets tackled Pharmaceutical & Biotechnology companies, Research Centers, Government Institutions

Size 12

Technology Requests · HealTH 127

Page 128: Biotechnology Basque Country

promoter organization identification

organization name Proteomika , S.L.

contact Daniel Nagore

email [email protected]

phone +34 944 064525

fax +34 944 064526

description of the organization

Privately held biotechnological company

activity In vitro diagnostics

markets tackled Diagnostics of complex diseases and monitorization of response to treatments

Size <30

Technological partners to develop new ELISA products for monitoring biologic therapies

abStract of technology to exploit

Proteomika SL is a biotechnology company in the human diagnostic industry. Established in 2002 as a subsidiary of Progenika Biopharma, S.A., Proteomika uses its expertise in immunoassay development and biomarker discovery by proteomics to develop in vitro diagnostic and prognostic assays. We are specialized in assisting physicians in monitoring patients under treatment with biopharmaceuticals. Proteomika also owns several diagnostic immunoassays to measure a number of biological markers and protein microarrays technology for high throughput screening of biomarkers and autoimmune profiling in cancer, gynaecologic diseases and autoimmune conditions.

deScription

Diagnostic immunoassays are of relevance in clinical fi elds such as oncology. Our diagnostic immunoassays are comprised by proprietary monoclonal antibodies and recombinant antigens. Assays are highly sensitive and specific tools to measure single proteins or a panel of biomarkers in a broad spectrum of biofluids including serum, urine, plasma, broncoalveolar lavage, and sev-eral tissues. In a variety of formats and technologies, our immu-noassays serve as validation tools with the objective of develop-ing protein markers for routine in vitro diagnostics and monitor-ing patient response to treatment with biopharmaceuticals.

technical SpecificationS

Despite recent advances in biomarker discovery and develop-ment of IVD tests, there is a growing need for noninvasive pro-tein markers showing adequate levels of diagnostic sensitivity and specificity in several complex human diseases. Starting from its biomarker discovery platform Proteomika has developed sev-eral marker panels that are validated in several ELISA formats and bead-based arrays.

128

Page 129: Biotechnology Basque Country

marketS addreSSed:

Proteomika´s products are intended for the human diagnostic in-dustry. Briefly, Promonitor®, a set of ELISA immunoassays for bio-logical drug monitoring and prediction of the response in patients treated with anti-TNFa immunotherapies; Proimplant® a novel test in the analysis of the endometrial function. Other IVD fields of in-terest include non invasive early diagnosis of non-small cell lung cancer and endometriosis.

collaboration type:

We are interested in associations with partners in order to develop new products following the line of Promonitor® Kits.

In regards to the clinical collaboration, we are interested in es-tablishing long term collaborations with opinion leader physicians. Specific fields of interest are lung cancer, endometriosis, and im-munotherapy monitoring in autoimmune diseases like rheumatoid arthritis and Inflammatory Bowel Disease among others. Proteo-mika also establishes contract research collaborations with pharma and biotech companies, aimed at the discovery and validation of non-invasive diagnosis and development of new immunoassays.

kind of agreement Sought:

As an in vitro diagnostic biotechnological company we are in close contact with physicians and medical centres throughout the world. Our main interest is to access high quality sample cohorts from existing sample collections for biomarker validation in the mentioned fields and to establish clinical networks and multicenter studies. Proteomika also seeks to partner with pharmaceutical and biotechnological companies in the disease biomarker discovery and molecular diagnostic fields.

129

Page 130: Biotechnology Basque Country

promoter organization identification

organization name Laboratorium Sanitatis, S.L. Tecnalia (LABSAN)

contact Itziar Echevarría

email [email protected]

phone +34 902 760 000

fax +34 945 298217

description of the organization

Pharmaceutical Laboratory

activity Research and development of pharmaceutical products and services

markets tackled Pharma, Cosmetics, Clinics, Biotech, Medical Devices

Size SME

Pharmaceutical Products and Services

abStract of technology to exploit

We are looking for pharmaceutical and biotechnological companies, technological research centres and universities working in screening of new APIs that want to develop the formula and manufacturing processes.

We are looking for cosmetic and medical devices companies interested in formulating and GMP manufacturing.

deScription

Labsan offers specialised research and development services within the pharmaceutical, biotechnological, cosmetic and medi-cal devices sectors: Pharmaceutical product manufacturing of in-dustrial and Innovative Medicinal Products, scaling-up services, medication for clinical trials, analytical development/validation, and process design, optimization and validation.

Our manufacturing facilities comply with Good Manufacturing Certificate (cGMP) and ISO 23485 for medical devices. The labo-ratory is specifically equipped for the manufacturing of the fol-lowing dosage forms:

• Solid forms: Tablets, capsules.

• Semi-solids forms: Creams, ointments, emulsions, gels.

• Liquid forms: Syrups, drops, solutions.

technical SpecificationS

All technology, equipment, product or service sought has to com-ply with pharmaceutical standards.

130 Technology Requests · HealTH

Page 131: Biotechnology Basque Country

marketS addreSSed:

• Pharma

• Cosmetics

• Biotech

• Medical Devices

collaboration type:

We are looking for any kind of collaboration with pharma com-panies, cosmetic companies, biotech companies, research centres and universities.

kind of agreement Sought:

Technical cooperation, commercial agreement, partners for project collaboration.

Technology Requests · HealTH 131

Page 132: Biotechnology Basque Country

132

Page 133: Biotechnology Basque Country

Business Development

Services

133

Page 134: Biotechnology Basque Country

promoter organization identification

organization name ELuR S.L.

contact Eduardo Torre

email [email protected]

phone +34 902 106 536

fax +34 946 740 985

description of the organization

ELuR, S.L. was founded in 2000 and headquartered in Bizkaia. Since then, it has settled into the national market. From our branches in Mungia (Bizkaia) and San Sebastián de los Reyes (Madrid) we provide services of engineering, design and cleanroom installations, air treatment, electricity, automation, biosecurity and biotechnology.

activity ELuR ‘s main objective is to meet the needs, and in so doing we offer turnkey services or efficient collaborations according to any new challenge demanded by our clients.

markets tackled Biotechnology and Pharmaceutical Industry.

Size 31 employ

Your Partner for Biotechnology facilities and Pharmaceutical Industry

abStract of technology to exploit

ELUR S.L. provides professional solutions in all its undertakings. Always undergoing technical innovation in answer to a market facing continuous technological challenges.

Our work philosophy is service and quality. Not only achieving our client’s expectations but excelling ourselves in the task

deScription

According to clients’ needs, ELUR offers solutions at any stage of the project ensuring the quality of the installation.

• CONSULTANCY. Development of user requirements, Development of Technical Specifications, Advice on current regulations, Facilities Analysis, Technical feasibility studies, Energy saving.

• PROJECTS AND DESIGN. PMV – DQ Qualifications, Quality Management, Detailed engineering, Electric projects, Air conditioning projects, Pneumatic projects, Industrial cooling projects, Finite Element Analysis, Virtual designs.

• DIRECTION OF WORKS. Supervision of Works, Coordination, Execution of works and installations .

• VALIDATION. Projects dealing with official bodies, Validation protocols (IQ, OQ, PQ), Validation management (Processes, Own supplies, Third-party supplies).

• MAINTENANCE POST-SALES. Comprehensive maintenance contract, Repairs, Training, Re-qualifications

134 Business Development - SERVICES

Page 135: Biotechnology Basque Country

marketS tackled

International research groups in Neuroscience, human diagnostic, human cognitive rehabilitation, health services and medical profes-sionals who works in the Neuroscience. We work for researches, health services and medical professionals who work in the field of brain function and behaviour.

marketS addreSSed

• GLOBAL SOLUTIONS TO DIFFERENT SECTORS.

• HOSPITALS. Parenteral Area, Infectious Disease Area, Burns unit, Immunodepression Area, Operating theatres

• PHARMACIES. Pharmaceutical Laboratories, Biopharmaceutical Laboratories, Sterile Areas, Oral, Cytostatic Areas

• INDUSTRIAL. Herbalist’s, Cosmetics, Food industry (meat, dairy), Packaging, Processes

• TECHNOLOGY. Optical technology, Aeronautics, CSIC and research, Microelectronics, Aerospace, Micromechanics, Fine chemicals

• R&D. Biotechnology, Cell therapy, Animal facilities, Tissue Banks, Blood Banks

• BIOSECURITY. RDI, Chemical laboratories, Biological laboratories

Business Development - SERVICES 135

Page 136: Biotechnology Basque Country

promoter organization identification

organization name NESPLORA - Neuroscience Support Systems, SL

contact Flavio Banterla

email [email protected]

phone +34 943 30 84 31

fax -

description of the organization

We are small enterprise, spin-off of two research groups (Computational Intelligence and Animal Behaviour and Psychobiology) of the university of the Basque Country.

activity Design, Research, Development and Commercialization of Technology Solutions for the Neuroscience.

markets tackled Researches, health services and medical professionals who work in the Neuroscience.

Size SME

Research and Development of Technology solutions for the Neuroscience: Diagnostic, Treatment, Basic Research and Prevention

deScription

We design, research and develop technology solutions for the Neuroscience, that are focused to the human diagnostic and treatment, the research and prevention in Neuroscience.

• We design new solutions for the Neuroscience in close collaboration with hospitals and research groups.

• Our experts can help neuroscientists to focus the best technology for the realization of their idea.

• We capture human behavioural data using new technologies as computer vision, virtual reality, gesture

recognition and trajectory recognition.

• We study behavioural data using our Knowledge Management platform, that assure the increase of the knowledge of the pathology.

marketS tackled

International research groups in Neuroscience, human diagnos-tic, human cognitive rehabilitation, health services and medical professionals who works in the Neuroscience. We work for re-searches, health services and medical professionals who work in the field of brain function and behaviour.

collaboration type

Co-development, research, validation and commercial.

We would like to meet international research groups that are interested in the development of their own solution for the diag-nostic or rehabilitation in Neuroscience.

Our solutions are non-invasive and exclusively based on be-havioural data, so we are also interested in share the validation of our solutions. For that we need to try our solutions, validate and public the results in scientific papers. The best collaborators would be hospitals, clinic centers, day centers who can organize groups of people and do a study using our solutions.

kind of agreement Sought

Technology Transfer Agreement, Shared R.T.D., Shared Develop-ment, Basic Research, Commercial.

136 Business Development - SERVICES

Page 137: Biotechnology Basque Country

Business Development - SERVICES 137

Page 138: Biotechnology Basque Country

BioChemTech Sector Group

http://een.ec.europa.euhttp://eenbasque.net

cristina oyónSPRI - Iniciativas Estraté[email protected]

arturo antónSPRI - Basque Enterprise Europe [email protected]

Alameda de Urquijo, 36 - 4º (Edificio Plaza Bizkaia)48011 Bilbao (Spain)Tel: +34 944 037 038 Fax: +34 944 037 022